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Abstract
Sudden cardiac arrest is a leading cause of death and disability in the US, with over 500,000 events annually
and <20% surviving to hospital discharge. Half of survivors suffer some degree of neurologic disability from
massive ischemic injury and subsequent reperfusion processes. It therefore is vital to evaluate cardiac arrest at
both population and clinical levels to improve outcomes. In response, this dissertation had three objectives.
First, we examined whether hospital performance could be benchmarked using administrative data, which is
more common than registry data. Two risk standardization models were developed using logistic regression
involving 2453 patients treated from 2000-2015 at University of Pennsylvania Health System hospitals.
Registry and administrative data were accessed for all patients and used to develop separate risk
standardization models with survival to hospital discharge as the outcome and the registry model considered
the “gold standard.” The administrative model had a receiver operating characteristic (ROC) area of 0.891
(95% CI: 0.876-0.905) compared to a registry area of 0.907 (95% CI: 0.895-0.919), indicating that risk
standardization can be performed using administrative data. Second, serial temperatures were collected
during the 72 hours following targeted temperature management (TTM) and rewarming on 465 TTM-treated
patients from the Penn Alliance for Therapeutic Hypothermia (PATH) registry, of whom 179 (38.5%) had at
least one pyrexic temperature (≥38oC). Higher maximum temperature was associated with worse neurologic
outcome and lower survival in pyrexic patients. Pyrexia duration and outcomes were not related, unless
duration was calculated as hours at or above 38.8oC; at those elevated temperatures, longer duration was
associated with worse neurologic and survival outcomes. Third, serial temperatures were collected during the
72 hours post-arrest on 578 PATH patients not treated with TTM; 228 (39.5%) had at least one pyrexic
temperature. Worse neurologic and survival outcomes were associated with increasing maximum temperature,
the combination of higher maximum temperatures and longer durations at an elevated temperature, and
timing of onset of pyrexia between 10.2-24.5 hours post-arrest. This work establishes the potential for using
administrative data to create new opportunities to compare hospital performance regarding cardiac arrest and
extends knowledge on clinical implications of post-arrest temperature on outcomes.
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ABSTRACT 
 
SUDDEN CARDIAC ARREST: NOVEL USES OF RISK STANDARDIZATION AND 
POST-ARREST BODY TEMPERATURE TO IMPROVE OUTCOMES 
Anne V. Grossestreuer, M.S. 
Benjamin S. Abella, M.D., M.Phil. 
Sudden cardiac arrest is a leading cause of death and disability in the US, with over 
500,000 events annually and <20% surviving to hospital discharge. Half of survivors 
suffer some degree of neurologic disability from massive ischemic injury and subsequent 
reperfusion processes. It therefore is vital to evaluate cardiac arrest at both population and 
clinical levels to improve outcomes. In response, this dissertation had three objectives. 
First, we examined whether hospital performance could be benchmarked using 
administrative data, which is more common than registry data. Two risk standardization 
models were developed using logistic regression involving 2453 patients treated from 
2000-2015 at University of Pennsylvania Health System hospitals. Registry and 
administrative data were accessed for all patients and used to develop separate risk 
standardization models with death prior to hospital discharge as the outcome. The 
registry model considered the “gold standard.” The administrative model had a receiver 
operating characteristic (ROC) area of 0.891 (95% CI: 0.876-0.905) compared to a 
registry area of 0.907 (95% CI: 0.895-0.919), indicating that risk standardization can be 
performed using administrative data. Second, serial temperatures were collected during 
72 hours following targeted temperature management (TTM) and rewarming on 465 
TTM-treated patients from the Penn Alliance for Therapeutic Hypothermia (PATH) 
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registry, of whom 179 (38.5%) had at least one pyrexic temperature (≥38C). Higher 
maximum temperature was associated with worse neurologic outcome and lower survival 
in pyrexic patients. Pyrexia duration and outcomes were not related, unless duration was 
calculated as hours ≥38.8C; at those elevated temperatures, longer duration was 
associated with worse neurologic and survival outcomes. Third, serial temperatures were 
collected during the 72 hours post-arrest on 578 PATH patients not treated with TTM; 
228 (39.5%) had at least one pyrexic temperature. Worse neurologic and survival 
outcomes were associated with increasing maximum temperature, the combination of 
higher maximum temperatures and longer durations at an elevated temperature, and 
timing of onset of pyrexia between 10.2-24.5 hours post-arrest. This work establishes the 
potential for using administrative data to create new opportunities to compare hospital 
performance regarding cardiac arrest and extends knowledge on clinical implications of 
post-arrest temperature on outcomes.  
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CHAPTER 1 
Cardiac arrest risk standardization using administrative data compared to registry 
data 
 
INTRODUCTION 
Cardiac arrest is a challenge to prevent, manage, and study as a clinical condition 
in the real world. Differences in definitions (Nishiyama et al. 2014), termination-of-
resuscitation rules (Sasson et al. 2009; Sasson et al. 2010), data collection (Cummins et 
al. 1991; Jacobs et al. 2004; Nishiyama et al. 2014) and participation in registries (Sasson 
et al. 2010), as well as patient heterogeneity (Cabanas et al. 2015) make even capturing 
the incidence of sudden cardiac arrest difficult (Cummins et al. 1991; Grasner et al. 2011; 
Jacobs et al. 2004; Morrison et al. 2008; Nishiyama et al. 2014). This diversity can lead 
to differences in outcomes that may be influenced by variations in care (Carr et al. 2009a; 
Carr et al. 2009b; Chen et al. 2015; Fredriksson, Herlitz, Nichol 2003; Heffner et al. 
2012; Hinchey et al. 2010; Kellum, Kennedy, Ewy 2006; Kellum et al. 2008; Lund-
Kordahl et al. 2010; Nichol et al. 2008; Nichol and Soar 2010; Spaite et al. 2014; Stub et 
al. 2015). However, recent initiatives to change both intra- and post-arrest care have led 
to improved outcomes (Adielsson et al. 2011; Fothergill et al. 2013; Fugate et al. 2012; 
Hollenberg, Svensson, Rosenqvist 2013; Iwami et al. 2009; Iwami et al. 2012; Japanese 
Circulation Society Resuscitation Science Study Group 2013; Kitamura et al. 2010; 
Kitamura et al. 2012; Neumar et al. 2008; Peberdy et al. 2010; Ro et al. 2013; Tagami et 
al. 2012; Weisfeldt et al. 2010; Wissenberg et al. 2013), highlighting the importance of 
performing these assessments. Additionally, the Institute of Medicine has recognized as a 
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priority the need for better cardiac arrest data collection and outcomes improvement 
(Becker, Aufderheide, Graham 2015).  
An important step to better understand the management of cardiac arrest involves 
comparing hospitals to determine which modalities and clinical protocols are associated 
with better outcomes (Donnino et al. 2012). Unfortunately, many US hospitals do not 
participate in a registry that provides such outcomes; contributing can be prohibitive in 
terms of financial and time costs (Khuri et al. 1998; Render et al. 2003). Additionally, 
voluntary participation in a registry may lead to selection bias (Ferreira-Gonzalez et al. 
2009). As registry data are the only current method for risk adjustment (Chan et al. 2013) 
in cardiac arrest, there is no way to enable fair comparison of observed mortality relative 
to expected mortality given patient characteristics across all US hospitals treating cardiac 
arrest.  
  To our knowledge, no studies have investigated whether administrative data on 
cardiac arrest, which have been shown to be effective in sepsis patients (Lagu et al. 
2011). Administrative data potentially are available for all hospitals in the U.S., could 
perform as well as registry data to accomplish risk standardization in order to study 
variability in cardiac arrest outcomes. If, as we hypothesized, administrative-type data 
perform as well as registry data in this population, we will have evidence that a tool for 
risk standardization can be developed and applied to hospitals across the US. Using data 
from a national cardiac arrest registry at the University of Pennsylvania and 
administrative data from the University of Pennsylvania Health System on the same 
cohort of cardiac arrest patients, we aimed to develop a method for risk-standardizing 
hospital survival after cardiac arrest using administrative data that is validated against one 
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using registry data. 
 
METHODS 
Data source 
The registry data were from the Penn Alliance for Therapeutic Hypothermia 
(PATH) database. PATH is an internet-based registry established by the University of 
Pennsylvania in 2010. PATH includes cardiac arrest data from pre-hospital, emergency 
department, and in-hospital settings. Potentially available to any US hospital, PATH 
supports the tracking of all patients who experience cardiac arrest and receive 
cardiopulmonary resuscitation. Cardiac arrest is defined in PATH as a loss of pulse with 
subsequent chest compressions. Each patient record in PATH consists of 30 required data 
elements based on the Utstein template (Jacobs et al. 2004; Perkins et al. 2014). One 
hundred additional data elements are required for research participation. Further optional 
data elements are also available to address specific research questions. Data are entered 
via a secure website and maintained on a password-protected encrypted server at the 
University of Pennsylvania. Data are collected retrospectively at each of the participating 
institutions. Before entering data, data abstractors undergo structured training including 
mock case entry and case review. All participants are provided with a standardized data 
dictionary and are subject to a formal auditing process (Leary et al. 2013). PATH 
currently supports 34 member hospitals from 19 US states and includes data from over 
5000 cardiac arrests. Exclusion criteria are age <18 years, traumatic etiology of arrest, 
active do-not-resuscitate orders prior to arrest, and lack of administrative data. This study 
was approved by the University of Pennsylvania Institutional Review Board.  
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Administrative data for this study were from the Penn Data Store, a research 
initiative at the University of Pennsylvania that integrates clinical data on all University 
of Pennsylvania Health System (UPHS) patients. All available administrative information 
on cardiac arrest patients (defined as having an ICD-9 code of 427.5) seen at three UPHS 
hospitals, the Hospital of the University of Pennsylvania, Penn Presbyterian Medical 
Center, and Pennsylvania Hospital, was queried, and consisted of demographics, 
procedure codes, diagnosis codes, and drug and other orders. These data were then 
matched on medical record number to records from the PATH database. Only the patients 
who have both registry data in PATH and administrative-type data in Penn Data Store 
were included in the risk standardization model building.   
Model building 
Recommended guidelines for conducting risk adjustment for trauma, another 
time-sensitive critical illness, have been published, allowing comparison of trauma center 
outcomes (Newgard et al. 2013). Using these methods as guidance, we applied and 
adapted that approach to develop two risk standardization models.  
First, we developed a method for risk-standardization using registry data for in- 
and out-of-hospital cardiac arrest patients using logistic regression with survival to 
discharge as the outcome. Cox regression was not used because our interest was not in 
time to the outcome of interest (death) but in whether death had occurred by hospital 
discharge. A total of 17 variables (Table 1) were modeled as potential independent, 
adjustor variables. The variables were selected to match, to the extent possible, the 
variables in the Utstein template (Jacobs et al. 2004; Perkins et al. 2014). These variables 
were modeled through a backward stepwise variable selection process (using a p<0.25 to 
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enter the model) (Maldonado and Greenland 1993; Mickey and Greenland 1989) to 
generate the most parsimonious model and evaluate changes in predictive ability. 
Variables that did not contribute to prediction were excluded from the final model. The 
final model included race, whether the arrest was witnessed, initial rhythm, age, if intra-
arrest epinephrine was given, cumulative dose of intra-arrest epinephrine, if patient was 
treated with TTM, year of arrest, and whether the patient regained consciousness shortly 
post-arrest (defined as ineligibility for TTM due to purposeful following of commands). 
Significant missing data (more than 5% but no more than 15%) were addressed through 
multiple imputation, conducted using 20 iterations and then combined using the “mi 
estimate” Stata command (Cañette and Marchenko 2013; Newgard et al. 2013; StataCorp 
2013). A final logistic regression model generated the risk-adjusted predicted probability 
of death for each patient, ranging from 0 to 1, with higher values indicating a higher 
predicted probability that a given patient had died by hospital discharge. This final 
predictive model was assessed using conventional techniques including the Hosmer-
Lemeshow goodness-of-fit statistic to assess calibration, calibration curves, c-statistic to 
assess discrimination, and Akaike information criterion value to compare model fit and 
composition across multiple models. The resulting model was considered the gold 
standard for risk adjustment for our study purposes. In order to accommodate for multiple 
imputation, we used two strategies once arriving at a final model to derive a predicted 
probability for each patient: the predicted value of each of the imputed data sets averaged 
per patient using the “mim” suite of commands (Galati, Royston, Carlin 2013) and by 
using the imputed dataset closest to the median receiver operating characteristic (ROC) 
curve with the better Hosmer-Lemeshow goodness-of-fit statistic. 
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To verify that there are not significantly better modeling methods of risk 
standardization in this population, we repeated this analysis using hierarchical mixed 
effect models and generalized estimating equations. Bayesian analysis was not explored, 
due to its incompatibility with multiple imputation, and linear and Poisson regression 
were not used because of the nature of the outcome and our question of interest 
(dichotomous survival) (Newgard et al. 2013). 
Next, we developed a method for risk-standardizing hospital survival using 
administrative data. To identify candidate variables for exploration, we queried all 
available diagnostic codes, procedure codes, demographics, and orders for all patients 
with an ICD-9 code for cardiac arrest (427.5). We then isolated all unique diagnosis 
codes, procedure codes, and orders. These were assessed by two physician-fellows in 
resuscitation science to determine, by consensus, which of these should be explored as 
candidate variables due to their possible relationship to survival. Each identified 
candidate variable then was tested in univariate logistic regression against the outcome of 
interest (death at hospital discharge).  
We next employed the same logistic regression methodology to the administrative 
data as was done with the registry data, developing a logistic regression model using 
death at hospital discharge as the outcome. The administrative candidate variables were 
modeled as potential independent, adjustor variables through a manual forward stepwise 
variable selection process (using a univariate p<0.25 to enter the model) (Maldonado and 
Greenland 1993; Mickey and Greenland 1989). Variables that did not contribute to 
prediction were excluded from the final model. Variance inflation factors were checked 
and collinear variables were collapsed or omitted. There was no missing data in the 
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administrative data set that was greater than 1%. The final logistic regression model 
generated the risk-adjusted predicted probability of death for each patient; this model was 
used in comparison to the “gold standard” registry model. 
Finally, we assessed the performance of the risk standardization done using 
administrative data to the performance of the “gold standard” risk standardization done 
using registry data.  The results for both sets of analysis were reported as c-statistics, 
calibration plots, and Bland-Altman plots. To evaluate the models against each other, we 
used Bland-Altman plots to assess mean difference in predicted values and the percentage 
of values outside the limits of agreement, defined as two standard deviations of the mean 
difference (Giavarina 2015), a Hosmer-Lemeshow plot of the performance of the 
predicted values from each model compared to the observed values, and tests of the 
equality of receiver operating characteristic (ROC) areas between models. The last 
assessment, a test of the equality of ROC areas between models, was chosen a priori as 
the final determination for model comparison, with significance assessed at p<0.05.  
In the primary analysis, all patients will be included. However, due to differences 
in out-of-hospital versus in-hospital cardiac arrest, the same methodology will be applied 
to those two subgroups to evaluate differences in model performance based on location of 
arrest. 
 
RESULTS 
Patient population 
 There were 2453 patients who had both administrative and registry data between 
1/2000-4/2015. This cohort had a median age of 63 (IQR: 51, 74) years; 57.8% of these 
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patients were male, 44.1% white, 24.8% had an initial shockable rhythm of ventricular 
fibrillation or pulseless ventricular tachycardia (VF/VT), 60.6% had a presumed cardiac 
etiology of arrest, 53.7% had an out-of-hospital cardiac arrest (OHCA), 26.3% of OHCAs 
received bystander CPR, 74.8% had a witnessed arrest, and 83.5% had intra-arrest 
epinephrine given, with a median dose of 2 (IQR: 0, 3) mg. The median duration of arrest 
was 11 (IQR: 5, 25) minutes, 62.5% had return of spontaneous circulation (ROSC), 
19.8% of patients received TTM, 17.4% of patients regained arousal shortly post-ROSC, 
25.8% of patients survived to hospital discharge, and 20.0% of patients had a favorable 
neurologic outcome (as defined as a Cerebral Performance Category [CPC] score of 1-2, 
an outcome measure which is commonly employed in the resuscitation literature 
(Bernard et al. 2002; Hypothermia after Cardiac Arrest Study Group 2002; Nielsen et al. 
2013; Perkins et al. 2014). 
Registry risk standardization 
 There were 2622 cardiac arrests in PATH between 1/2000-4/2015 and 2453 of the 
arrests matched with administrative data (93.6%). The patients that did not match with 
administrative data were significantly more likely to have initial shockable rhythms, to be 
African-American, to have a cardiac etiology of arrest, to have an OHCA, to have a 
witnessed arrest, to not receive epinephrine intra-arrest and to receive a lower dose if 
given, to have a longer duration of cardiac arrest, to achieve ROSC, to not receive TTM, 
to regain consciousness shortly post-arrest, to survive to hospital discharge and to have an 
CPC score of 1 or 2 at hospital discharge (Appendix Table 1).  
The c-statistic in the final model containing nine predictor variables using the 
average predicted values from each imputation was 0.9119 (95% CI: 0.9003-0.9235) with 
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a median Hosmer-Lemeshow goodness-of-fit statistic of 0.36 (IQR: 0.19-0.58). The final 
model using the median imputed dataset had a c-statistic of 0.9078 (95% CI: 0.8959-
0.9197) with a Hosmer-Lemeshow goodness-of-fit statistic of 0.38. However, when 
evaluating the risk standardization with Bland-Altman plots using the model composed of 
the average predicted values from all imputations, we found a much worse fit in terms of 
Pitman’s test of difference in variance than when using the single imputed dataset. 
Therefore, we chose to use the values from the median imputed dataset as the “gold 
standard”. The ROC area used for comparison to administrative modeling was slightly 
different due to a few missing ages in the administrative dataset (<1%). 
 Use of generalized estimating equations controlling for clustering by year 
provided identical results (c-statistic: 0.9078 [95% CI: 0. 0.8959-0.9197]). Use of a 
mixed effects model with year as a random intercept resulted in an ROC area of 0.9147 
(95% CI: 0.9028-0.9267), which was not statistically different from either the logistic 
regression or the generalized estimating equations approach. 
Administrative risk standardization 
 Penn Data Store reported 5424 patients between 1/2000-4/2015 with an ICD-9 
code of 427.5. These patients were 57.3% male, 50.1% white, and had a median length of 
hospital stay of 6 (IQR: 1, 17) days. Forty-five percent of the patients with an ICD-9 code 
for cardiac arrest were matched with registry data. On these 5424 arrests, there were 1423 
unique procedure codes, 2001 unique drugs, 5632 unique orders, and 4723 unique 
diagnosis codes (13,792 candidate variables including race, sex, and age). 
 A list of all unique procedure codes, drug orders, other orders, and diagnosis 
codes was compiled for assessment by two physician-fellows in resuscitation science 
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involved in this study. Both fellows eliminated any variables assessed as irrelevant for 
predicting survival outcome in cardiac arrest patients. Any variable eliminated by one 
fellow but not the other remained eligible for exploration. After the fellows’ assessment, 
1719 (12.5%) potential variables remained. Each of these was then analyzed in univariate 
logistic regression with survival to discharge as the outcome. Any variable with a p-value 
of <0.25 remained eligible for the model, which resulted in 317 variables. Using manual 
forward selection in order of lowest p-value to highest, variables were then entered into 
the logistic regression model. Variables remained in the model if they improved the 
predictive value and were removed if they worsened the predictive value or if it remained 
the same. After analyzing all 317 variables, 133 remained in the model (Appendix Table 
2) with a c-statistic of 0.8905 (95% CI: 0.8757-0.9054) and a Hosmer-Lemeshow 
goodness of fit of 0.58. To get a c-statistic>0.80, only 15 variables were needed: codes 
37.94 (Implantation or replacement of automatic cardioverter/defibrillator, total system), 
96.72 (Continuous invasive mechanical ventilation for 96 consecutive hours or more), 
96.04 (Insertion of endotracheal tube), 43.11 (Percutaneous [endoscopic] gastrostomy 
[PEG]), 37.22 (Left heart cardiac catheterization), 414.01 (Coronary atherosclerosis of 
native coronary artery), 507 (Pneumonitis due to solids and liquids), 599 (Urinary tract 
infection, site not specified), 39.61 (Extracorporeal circulation auxiliary to open heart 
surgery), 37.23 (Combined right and left heart cardiac catheterization), 427.41 
(Ventricular fibrillation), 88.53 (Angiocardiography of left heart structures), year of 
arrest, respiratory failure (composite of 518.81, 518.83, 518.84, and 799.1), and presence 
of a DNR (composite of V49.86 and order for DNR-C [comfort measures]). The ROC 
curve for this reduced model was 0.8004. To assess the performance of other models, we 
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used a generalized estimating equation model controlling for clustering by year and a 
mixed effects model with year as a random intercept. Both of these models provided 
identical results to the model using logistic regression (c-statistic: 0.8905 [95% CI: 
0.8757-0.9054]).  
Comparing risk standardization models 
Using the “rocgold” Stata command, the registry data ROC area using the 
imputation with a value closest to the median was 0.9069 (95% CI: 0.8949-0.9189) 
compared to an administrative ROC area of 0.8905 (95% CI: 0.8755-0.9052). This was 
an insignificant difference (p=0.075; Figure 1). Controlling for trend with a Bland-
Altman plot, we found that the mean difference between the two methods of risk 
standardization was 0.002 (95% CI: -0.009-0.014) with a non-significant Pitman's test of 
difference in variance (p=0.437), which we conclude represents good agreement; the line 
of equality falls within the confidence interval of the mean difference and only 4.97% of 
the data points lie outside the recommended range of two standard deviations of the mean 
difference. As seen in Figure 2, there is more agreement in the patients with a predicted 
poor outcome (Giavarina 2015). Both models had good calibration, as seen in Figures 3 
& 4 and by non-significant Hosmer-Lemeshow goodness-of-fit statistics.  
Out-of-hospital cardiac arrest  
In patients with an out-of-hospital cardiac arrest, 231 of the 1719 candidate 
variables identified by the two resuscitation science physician-fellows had a univariate 
relationship with survival of p<0.25. Using manual forward selection in order of lowest 
p-value to highest, variables were entered into the model, remaining in the model if the 
predictive value was improved and removed if the predictive value worsened or remained 
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the same. After analyzing all 231 variables, 98 remained in the model (Appendix Table 3) 
with a c-statistic of 0.9346 (95% CI: 0.9178-0.9515) and a Hosmer-Lemeshow goodness 
of fit statistic of 0.08. To get a c-statistic>0.80, only 5 variables were needed: codes 96.72 
(Continuous invasive mechanical ventilation for 96 consecutive hours or more), 96.04 
(Insertion of endotracheal tube), 37.22 (Left heart cardiac catheterization), 414.01 
(Coronary atherosclerosis of native coronary artery), and year of arrest. The ROC area for 
this reduced model was 0.8011. 
The best model for the registry data was the model developed for use in both in- 
and out-of-hospital arrests. This model had an ROC area of 0.9447 (95%CI: 0.9328-
0.9567) when limited to OHCAs. Comparing the registry and administrative models, 
there was no significant difference in the ROC areas (p=0.316; Figure 5). Less than 5% 
of the data points in the Bland-Altman plot lie outside the recommended range of two 
standard deviations of the mean difference (Appendix Figure 1). 
In-hospital cardiac arrest 
Inpatients with an in-hospital cardiac arrest, 172 of the 1719 candidate variables 
identified by the two resuscitation science physician-fellows had a univariate relationship 
with survival of p<0.25. Using manual forward selection in order of lowest p-value to 
highest, variables were entered into the model, remaining in the model if the predictive 
value was improved and removed if the predictive value worsened or remained the same. 
After analyzing all 172 variables, 100 remained in the model (Appendix Table 4) with a 
c-statistic of 0.8673 (95% CI: 0.8447-0.8898) and a Hosmer-Lemeshow goodness of fit 
statistic of 0.065. To attain a c-statistic>0.80, 18 variables were needed: 96.71 
(Continuous invasive mechanical ventilation for less than 96 consecutive hours), 96.72 
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(Continuous invasive mechanical ventilation for 96 consecutive hours or more), 599 
(Urinary tract infection, site not specified), 43.11 (Percutaneous [endoscopic] 
gastrostomy [PEG]), 37.22 (Left heart cardiac catheterization), 37.94 (Implantation or 
replacement of automatic cardioverter/defibrillator, total system), V49.86 (presence of a 
DNR), 0.17 (infusion of a vasopressor),  429.83 (Takotsubo syndrome), 995.92 (Severe 
sepsis), 997.31 (ventilator-associated pneumonia), 8.45 (Intestinal infection due to 
clostridium difficile), 37.72 (Initial insertion of transvenous leads [electrodes] into atrium 
and ventricle), 50.59 (liver transplant), 570 (acute necrosis of liver), 38.97 (Central 
venous catheter placement with guidance), 276.2 (acidosis), and 88.72 (diagnostic 
ultrasound of heart). The ROC area for this model is 0.8003. 
The best model for the registry data was the model developed for use in both in- 
and out-of-hospital arrests. This model had an ROC area of 0.8629 (95% CI: 0.8412-
0.8846) when restricted to in-hospital arrests. Comparing the registry and administrative 
models, there was no significant difference in the ROC areas (p=0.781; Figure 6). Less 
than 5% of the data points in the Bland Altman plot lie outside the recommended range of 
two standard deviations of the mean difference (Appendix Figure 2). 
 
DISCUSSION 
In developing two risk standardization models with extremely small differences 
between their c-statistics (0.0164), we have identified that risk adjustment modeling for 
cardiac arrest can be performed using administrative data, which are readily available and 
less costly (Khuri et al. 1998; Render et al. 2003) and less challenging to compile and to 
access than registry data. We therefore have evidence that a tool developed using 
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administrative data is feasible and that this model can be optimized for all patients or 
stratified by location of arrest. This tool could be applied in research to identify 
variability in the management of cardiac arrest and to learn from effective modalities and 
protocols to allow hospitals identify opportunities for improvement.  
Other studies have used risk standardization in the context of in-hospital cardiac 
arrest. One, using nine variables in their model of in-hospital cardiac arrest in the United 
States, found a c-statistic of 0.74, and was successful in risk standardizing hospital 
survival rates (Chan et al. 2013). Another study of in-hospital cardiac arrest done in the 
U.K. found a c-statistic of 0.81 (Harrison et al. 2014). In our work, we had a similar c-
statistic in both our registry and administrative models when limited to in-hospital arrests. 
In the U.S., there has been found to be a 42% difference in the odds of survival in 
in-hospital arrests even after risk adjusting the patient population for comparison 
(Merchant et al. 2014). Hospital-level interventions have been shown to be effective 
(Adielsson et al. 2011; Fothergill et al. 2013; Fugate et al. 2012; Hollenberg, Svensson, 
Rosenqvist 2013; Iwami et al. 2009; Iwami et al. 2012; Japanese Circulation Society 
Resuscitation Science Study Group 2013; Kitamura et al. 2010; Kitamura et al. 2012; 
Neumar et al. 2008; Peberdy et al. 2010; Ro et al. 2013; Tagami et al. 2012; Weisfeldt et 
al. 2010; Wissenberg et al. 2013), and hospitals that perform well with regard to in-
hospital cardiac arrest have also been found to be better at preventing cardiac arrest 
(Chen et al. 2013). Therefore, adequate comparisons, such as those provided using risk 
standardization, are vital to improve patient care and outcomes.  
A recent study called into question the utility of administrative data for 
identifying out-of-hospital cardiac arrest (Coppler et al. 2016). Investigators queried ICD-
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9 codes for cardiac arrest as well as VF, paroxysmal ventricular tachycardia, ventricular 
flutter, and respiratory arrest and found that only 40% of patients who had these ICD-9 
codes had an out-of-hospital cardiac arrest upon chart review. Similarly, we found that 
45% of the patients with an ICD-9 code for cardiac arrest were matched with registry 
data, although our study only included one ICD-9 code as well as both in- and out-of-
hospital cardiac arrests. Although 94% of the cardiac arrests in the registry were able to 
be matched to administrative data, there were some significant differences between the 
patients who were matched and those who were not. Interestingly, and in concordance 
with the above study, all patients who were not matched were able to be successfully 
resuscitated, leading to the unmatched patients having significantly better neurologic and 
survival outcomes. Despite our ability to risk standardize in a comparable way to registry 
data, we do not currently have a way to accurately capture administrative data on the 
patient population in question. Further work is needed to develop methods to identify this 
population in administrative datasets as well as to elucidate the scope of the problem. 
To properly build a nationally representative tool, clustering by site may be 
problematic and, although we found similar results using logistic regression compared to 
generalized estimating equations and hierarchical mixed effects modeling in our study of 
a single health system, those methods may be warranted in multi-site analysis. However, 
if the goal is to compare risk-standardized hospital performance, controlling for 
clustering by hospital may smooth out important differences at the hospital level; in that 
case, logistic regression would be encouraged. 
The data from PATH have the limitations of data from any retrospective registry, 
including the use of predefined data points and the risk of data entry errors or 
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inconsistencies.  Additionally, while administrative data potentially are available from all 
institutions and can be a reflection of “real world” situations, the information in these 
databases are not collected for research purposes, and often key variables are not 
recorded by administration, which have non-medical and non-research motivations for 
collecting information; these motivations can lead to documentation that might not match 
with research documentation. Finally, the data collected by the University of 
Pennsylvania Health System may differ from that collected at other institutions, despite 
having many common elements, limiting generalizability. 
 
CONCLUSION 
 This study serves as evidence that risk standardization using administrative data is 
comparable to that of registry data in the context of cardiac arrest. The critical gap of 
only having information on the performance of a subset of hospitals that participate in a 
registry potentially could be addressed by providing support for a new method that may 
identify hospital variability. This could lead to the identification of successful strategies 
at high-performing hospitals and the targeting of low-performing hospitals for 
intervention. Future investigations into expanding this methodology to include more sites 
may lead to a new tool for nationwide risk standardization to allow benchmarking and 
comparison of hospitals in terms of expected to observed mortality to identify high- and 
low-performing hospitals.  
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CHAPTER 2 
Degree of temperature elevation is associated with neurologic and survival outcomes 
in resuscitated cardiac arrest patients with post-rewarming pyrexia  
 
INTRODUCTION 
Significant morbidity and long-term impairments are common in cardiac arrest 
survivors (Cronberg et al. 2015; Moulaert et al. 2009; Nichol et al. 2015; Raina et al. 
2008; Smith et al. 2015). Approximately half of survivors suffer some degree of 
neurologic disability (Moulaert et al. 2009), resulting from ischemic injury occurring 
during no- and low-flow states as well as reperfusion injury occurring after restoration of 
native circulation. Collectively, this injury pattern is known as post-cardiac arrest 
syndrome (PCAS) (Adrie et al. 2002; Neumar et al. 2008). The adverse consequences of 
PCAS are frequent but variable, ranging from memory loss and proprioceptive 
derangements to persistent vegetative state (Moulaert et al. 2009; Raina et al. 2008), with 
impact on long-term function, health, and economic cost. Laboratory and clinical studies 
have suggested that elevated temperatures may exacerbate PCAS and subsequent 
neurologic injury (Leary et al. 2013; Polderman 2008; Suffoletto et al. 2009; Winters et 
al. 2013). 
Two randomized trials from 2002 demonstrated that post-arrest therapeutic 
hypothermia, also known as targeted temperature management (TTM), improves 
neurologic outcomes and survival. In these investigations, patients with out-of-hospital 
cardiac arrest (OHCA) with initial shockable rhythms were randomized to prompt 
cooling to 32-34°C for 12-24 hours or to passive temperature management (Bernard et al. 
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2002; Hypothermia after Cardiac Arrest Study Group 2002). Observational studies have 
confirmed these findings for OHCA from shockable rhythms and extended these findings 
to other types of cardiac arrest patients (Arrich and European Resuscitation Council 
Hypothermia After Cardiac Arrest Registry Study Group 2007; Busch et al. 2006; 
Lundbye et al. 2012; Oddo et al. 2006; Perman et al. 2015; Sagalyn et al. 2009; Schefold 
et al. 2009; Sunde et al. 2007). However, in part due to concerns that the control groups 
in both of the trials trended toward an elevated mean temperature and that a significant 
percentage of the control patients had pyrexia, a recent multicenter clinical trial (Nielsen 
et al. 2013) randomized both arms to active TTM, 33°C or 36°C. That study found no 
significant difference in terms of neurologic outcome or mortality, raising the question of 
whether reduced temperature is the protective component of TTM treatment or if 
protection is conferred by avoidance of elevated temperatures (Nielsen et al. 2013; 
Rittenberger and Callaway 2013). 
Development of markedly elevated temperatures (pyrexia), often a response to 
cellular injury, activation of inflammatory cascades, or infection (Saper and Breder 
1994), is frequent after cardiac arrest (Albrecht, Wass, Lanier 1998; Bouwes et al. 2012; 
Cocchi et al. 2014; Merchant et al. 2006; Pichon et al. 2007; Suffoletto et al. 2009; 
Takasu et al. 2001; Takino and Okada 1991; Winters et al. 2013; Zeiner et al. 2001). In 
diverse groups of patients with encephalopathy, markedly elevated temperatures are often 
a marker of poor outcomes and continued physiologic damage (Madden and DeVon 
2015; Niven and Laupland 2013; Sadaka 2013; Wrotek et al. 2011); however, whether 
this is true in post-arrest patients, particularly those treated with TTM, has yet to be 
clearly demonstrated.  A connection between pyrexia and worse outcomes in TTM-
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treated patients has received support in smaller retrospective studies (Bro-Jeppesen et al. 
2013; Gebhardt et al. 2013; Leary et al. 2013; Suffoletto et al. 2009; Winters et al. 2013), 
extending findings from earlier research done prior to the adoption of TTM as standard of 
care for treatment of anoxic encephalopathy (Albrecht, Wass, Lanier 1998; Langhelle et 
al. 2003; Zeiner et al. 2001). 
We hypothesized that TTM-treated patients with higher maximum temperatures 
following rewarming will have worse outcomes than those with lower maximum 
temperatures. We also hypothesized that patients with a longer duration of time at pyrexic 
temperatures and with earlier onset of pyrexia will have worse outcomes than those with 
a shorter duration.  
 
MATERIALS AND METHODS 
To evaluate how body temperature is related to outcomes after reestablishment of 
post-TTM normothermia, the Penn Alliance for Therapeutic Hypothermia (PATH) 
registry was queried. PATH is an internet-based registry established at the University of 
Pennsylvania in 2010 that includes cardiac arrest data from pre-hospital, emergency 
department, and in-hospital settings with a focus on post-arrest care. Potentially available 
to any US hospital, PATH supports tracking patients who experience cardiac arrest and 
receive cardiopulmonary resuscitation.  Each record in PATH consists of 30 data 
elements required from all participating institutions. One hundred additional data 
elements are required for institutions interested in using aggregate PATH data for 
research and further optional data elements are also available, including the capability to 
collect serial temperature measurements for successfully resuscitated patients. Data are 
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entered via a secure website and maintained on a password-protected encrypted server. 
Before entering data, data abstractors undergo structured training including mock case 
entry and case review. They are provided with a standardized data dictionary and subject 
to a formal auditing process (Leary et al. 2013). PATH currently supports 34 member 
hospitals and includes data from >5000 cardiac arrests. This project was approved by the 
University of Pennsylvania Institutional Review Board. 
Serial temperatures in the 72 hours following reestablishment of post-TTM 
normothermia (defined as reaching ≥36.5°C (Bro-Jeppesen et al. 2013) after a period of 
TTM treatment at temperature of ≤34.0°C) were evaluated.  Only patients who received 
TTM were included. Exclusion criteria were: age <18 years; traumatic etiology of arrest; 
death in the first 24 hours post-arrest; and no recorded temperatures during the applicable 
time period.  Patients also were excluded if target temperature (≤34°C) was never 
achieved or if they did not survive until completion of the rewarming phase of TTM. 
Both OHCA and in-hospital cardiac arrests (IHCA) were included.  Pyrexia was defined 
as 38.0°C, which has been used in other post-cardiac arrest studies on the effects of 
temperature (Benz-Woerner et al. 2012; Bouwes et al. 2012; Bro-Jeppesen et al. 2013; 
Gebhardt et al. 2013; Leary et al. 2013; Suffoletto et al. 2009; Winters et al. 2013). The 
primary outcome was neurologic status (measured by a Cerebral Performance Category 
(CPC) score dichotomized into “favorable” [CPC 1-2] and “unfavorable” [CPC 3-5]) and 
the secondary outcome was survival, both measured at hospital discharge. CPC has been 
used frequently as an outcome measure in prior clinical studies of cardiac arrest (Bernard 
et al. 2002; Hypothermia after Cardiac Arrest Study Group 2002; Nielsen et al. 2013). 
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There were three predefined exposures: maximum temperature, duration of pyrexia, and 
timing of onset of first pyrexic temperature (described below); maximum temperature 
was the primary analysis for which the study was powered. 
Maximum temperature 
Maximum temperature was defined as the highest recorded temperature in the 72 
hours after completion of TTM and rewarming. Multiple classification approaches were 
used to account for different possibilities of how maximum temperature related to 
outcomes: as a continuous variable, as an ordinal variable (by single temperature degree), 
and as a dichotomous variable (≥38.0°C, yes/no) in separate models. Of note, 118 (25%) 
of the patients evaluated for maximum temperature were included in previous work 
analyzing temperature elevation (Leary et al. 2013), although the patients in that study 
were followed for 48 hours instead of 72 hours and normothermia was defined as 37.0
o
C 
instead of 36.5°C. In that project, duration of pyrexia and timing of onset were not 
analyzed, so the patients were shared only when the effects of maximum temperature 
were analyzed. 
Duration of pyrexia 
The duration of time a patient experienced a certain temperature (or above) was 
calculated by assigning half of the time at a pyrexic temperature and half of the time at a 
non-pyrexic temperature when the patient transitioned between a pyrexic to a non-
pyrexic point (and vice versa). This calculation ended 72 hours post-rewarming and was 
repeated for every tenth of a degree, beginning with 38.0°C and ending with 42.2°C (the 
highest recorded temperature), to calculate the duration of time at or above each tenth of 
a degree. This was to assess whether duration of time at different temperatures (e.g. 
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38.0°C, 38.1°C, 38.2°C,...42.2°C) had different relationships to outcomes. Due to 
diversity in maximum temperature cutoffs across studies (Leary et al. 2013; Winters et al. 
2013), we analyzed each tenth of a degree to allow for a data-driven temperature 
threshold, as opposed to one that was predefined.  Each measure of time was treated first 
as a continuous variable (hours at temperature of interest) and then as an ordinal variable 
(divided by tertile) for each temperature cut point.  
Timing of onset of pyrexia 
Timing of onset of pyrexia was defined as the time between the patient’s return to 
normothermia and the first recorded pyrexic temperature (≥38°C). Timing of onset of 
pyrexia was assessed in 4 ways: early (first 36 hours post-normothermia) vs. late (second 
36 hours post-normothermia) onset, continuously (time from normothermia to first 
temperature ≥38°C in hours), in deciles, and in groups determined by Jenks natural break 
optimization, a statistical technique that uses the distribution of data to determine 
naturally occurring groupings (Cox 2007; Jenks 1967).  We also explored whether timing 
of onset of a temperature higher than 38.0°C was associated with outcomes; this 
temperature was chosen by comparing the univariate areas under the curve (AUCs) in 
relation to outcomes and selecting the temperature with the best discrimination. 
Patient types 
To combine all three elements of temperature examined in pyrexic patients, 12 
different patient categories were created based on naturally occurring groupings, as 
determined by Jenks natural break optimization (Cox 2007; Jenks 1967). There were two 
groups of maximum temperature (low versus high), two groups of duration of pyrexia 
(short versus long) and three groups of timing of onset of pyrexia (early versus middle 
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versus late; Appendix Table 5). Patient types then were analyzed with regard to 
outcomes. Due to some patient types having a low number of patients, 16 patient types 
were created involving just two dimensions of temperature and the analyses were 
repeated. 
Other data analysis 
For each dimension of temperature analysis, pre-, intra-, and post-arrest variables 
recorded in PATH (Appendix Table 6) were examined to explore potential confounders. 
Descriptive statistics used proportions, means and standard deviations, medians and 
interquartile ranges, and histograms to determine the proportion or prevalence and 
distribution of each variable. Each potential confounder was modeled separately with the 
outcome prior to use in a multivariate model. Any multivariate analyses used p<0.25 for 
covariate entry into the model (Maldonado and Greenland 1993; Mickey and Greenland 
1989). A parsimonious model was then created using backward stepwise procedures and 
likelihood ratio tests (Lemeshow and Hosmer 1982). Less than 15% of data on covariates 
was missing; missing data on covariates was addressed using multiple imputation 
conducted using 20 iterations (StataCorp 2013) and then combined using the “mi 
estimate” Stata command (Cañette and Marchenko 2013). Regression results were 
reported using odds ratios (ORs) and corresponding 95% confidence intervals (CIs). All 
data were analyzed using Stata v13.1 (Statacorp, College Station, TX). Additional 
analyses stratified by location of arrest (OHCA/IHCA) were performed, since IHCA 
patients are more likely to have multi-organ dysfunction and thus have elevated 
temperatures from other causes (Winters et al. 2013) and restricted to only patients with a 
maximum temperature ≥38.0°C. Finally, each component, maximum temperature, 
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duration of pyrexia, and timing of onset of pyrexic temperature, was tested to assess 
whether there was a univariate “threshold” value using receiver operating characteristic 
(ROC) curves and concordance statistics for discrimination. Post-estimation Hosmer-
Lemeshow goodness of fit tables were used to assess validity of each chosen cut-off. 
 
RESULTS 
Out of 465 TTM-treated patients from 13 hospitals in the PATH registry treated 
between 2005-2015 who met inclusion criteria, 179 (38.5%) had at least one pyrexic 
temperature (≥38°C). Pyrexic patients had a mean age of 56.0±16.0 years, 59.8% were 
male, 39.5% had an initial shockable rhythm, 69.4% had a witnessed arrest, 65.9% had a 
suspected cardiac etiology of arrest, and 83.2% were OHCA (Table 2). In terms of 
demographics, they only differed significantly from non-pyrexic patients in terms of age 
(pyrexic: 56.0±16.0 versus non-pyrexic: 60.4±16.4; p=0.001). However, the relationship 
between temperature and outcomes was not modified by age. 
Maximum temperature 
Our primary analysis, examining the effect of maximum temperature on 
neurologic outcome, controlling for age, duration of arrest, whether the arrest was 
witnessed, location of arrest, and initial rhythm, found that higher maximum temperature 
was associated with worse neurologic outcome (aOR: 0.30 [95% CI: 0.10-0.84], 
p=0.022) and lower survival (aOR: 0.25 [95% CI: 0.10-0.59], p=0.002; Table 3A) in 
patients who experienced post-rewarming pyrexia (Figure 7).  
When analyzing the role of pyrexia (maximum temperature: ≥38.0°C) versus non-
pyrexia (maximum temperature: <38.0°C), there was no significant relationship with 
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neurologic outcome (Table 3B), although there was a protective effect for pyrexia with 
regard to survival. Further analysis revealed that this was largely driven by IHCA 
patients, and that, when analyzing only patients with a maximum temperature of ≥37°C, 
the difference became non-significant.  
Duration of pyrexia 
There was no significant relationship between duration of pyrexia and outcomes 
unless duration was calculated as time a patient experienced temperature 38.8°C. This is 
the lowest temperature at which significant associations were found with regard to either 
the primary or secondary outcome. When measuring duration of temperature 38.8°C, 
there was a significant association between longer duration and worse neurologic 
outcome and lower survival (Table 3C). This relationship was similar when duration was 
measured against survival as time with temperature 38.9°C for neurologic outcome and 
for all subsequent tenths of a degree until 39.5°C.  
Timing of onset of pyrexia 
There was no significant relationship between the timing of onset of a temperature 
≥38.0°C and outcomes (aOR for neurologic outcome: 1.01 [95% CI: 0.99-1.04], p=0.233; 
aOR for survival: 1.02 [95% CI: 1.00-1.04], p=0.129). When pyrexia onset was measured 
as first time 38.7°C (the value with the best AUC in univariate analysis with regard to 
neurologic outcome [0.603 for neurologic outcome and 0.609 for survival]), there were 
no significant differences (aOR for neurologic outcome: 1.03 [95% CI: 0.99-1.08], 
p=0.168; aOR for survival: 1.01 [95% CI: 0.98-1.04], p=0.535).  
Patient types 
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Combining these elements into “patient types,” the patients with high 
temperatures always had lower (worse) point estimates than their low temperature 
counterparts, regardless of other factors. This difference was statistically significant for 
both neurologic outcome and survival when comparing the high temperature/early 
pyrexia group to the low temperature/early pyrexia group (CPC 1-2: OR: 0.33 [95% CI: 
0.14-0.77], p=0.011; survival: OR: 0.25 [95%CI: 0.08-0.79], p=0.018).  Compared to the 
low temperature/short duration group, the high temperature/long duration group was 
statistically worse in terms of neurologic status (OR: 0.36 [95% CI: 0.16-0.83], p=0.017). 
Comparing the low temperature/long duration group to the high temperature/long 
duration group and to the high temperature/short duration group, the higher temperature 
groups had worse survival (high temperature/long duration OR: 0.35 [95% CI: 0.16-
0.79], p=0.011; high temperature/short duration OR: 0.24 [95% CI: 0.07-0.90], p=0.034). 
There were no significant differences in either outcome for the patient types that included 
only duration and timing of onset. There were similar findings with regard to survival and 
neurologic outcome when the analysis was restricted to OHCA patients. 
Using all three temperature elements to determine “patient type”, there were 
significantly worse neurologic outcomes in the high temperature /long duration/early 
pyrexia group compared to the low temperature/long duration/early pyrexia group (OR: 
0.25 [95% CI: 0.08-0.77], p=0.016). There also were significantly worse survival 
outcomes in both the high temperature/long duration/early pyrexia group (OR: 0.31 [95% 
CI: 0.11-0.89], p=0.029) and the high temperature/short duration/early pyrexia group 
(OR: 0.12 [95% CI: 0.02-0.69], p=0.017) when compared to the low temperature/long 
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duration/early pyrexia group. There were similar findings with regard to survival and 
neurologic outcome when the analysis was restricted to OHCA patients. 
Other data analysis 
Each component, maximum temperature, duration of pyrexia, and timing of onset 
of pyrexia, was tested to examine if there was a univariate “threshold” value using 
receiver operating characteristic (ROC) curves and concordance statistics for 
discrimination. There was no cut-off value that was predictive of outcomes by itself (data 
not shown).   
 
DISCUSSION 
 In this study of serial temperatures examining TTM-treated post-arrest patients 
with pyrexia, there was a linear relationship between increasing maximum temperature 
and worsening neurologic and survival outcomes. There was no significant difference 
between the two other aspects of pyrexia, duration and timing, except, in the case of 
duration, where the risk of pyrexia increased with hours at a very elevated temperature 
(≥38.8°C). The importance of elevated temperatures in terms of post-arrest outcomes was 
reinforced when, using all three temperature elements to determine “patient type”, higher 
(more favorable) point estimates for all low temperature types compared to their high 
temperature counterparts were found, as well as statistically worse outcomes when 
comparing high temperature groups to their low temperature counterparts holding the 
other temperature elements constant. This suggests a critical link between high 
temperature and neurologic injury in patients experiencing post-rewarming pyrexia; thus, 
avoidance of high temperatures might improve outcomes.  
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Prior clinical studies have demonstrated the complexity of assessing the 
relationship between post-arrest temperature and outcomes. A recent investigation found 
that post-rewarming pyrexia was associated with favorable survival and neurologic 
outcomes. However, the mean maximum temperature in this work was 37.5°C (range: 
36.8-38.1°C), which supports the finding of this study that mild pyrexia may not provoke 
injury; in fact, markedly elevated temperatures may pose the problem with regard to 
outcomes (Lee et al. 2015). Other studies, defining pyrexia as ≥38.0°C, also found no 
relationship between being above this temperature and outcomes (Bouwes et al. 2012; 
Cocchi et al. 2014). A study analyzing both patients who received TTM and those who 
did not found that pyrexia (defined as ≥38.0°C) had no association with neurologic 
outcomes and was not associated with survival within the whole cohort or the patients 
who received TTM, but was associated with lower survival in patients who did not 
receive TTM, which could be explained by the difference in maximum temperature in the 
TTM group (37.61.0°C) compared to the non-TTM group (38.21.0°C) (Gebhardt et al. 
2013). Suffoletto et al found that patients experiencing post-arrest pyrexia (≥38.0°C) had 
worse survival and neurologic outcomes; however, the vast majority of the patients in this 
study did not receive TTM and mean maximum temperature in the pyrexic group was not 
reported (Suffoletto et al. 2009). 
Examining elevated pyrexia after TTM, defined as ≥38.5°C in the first 24 hours 
after TTM cessation, Winters et al found an association between a temperature ≥38.5°C 
and worse outcomes with regard both to survival and neurologic status, consistent with 
the results of this study (Winters et al. 2013). Similarly, our previous work (as mentioned 
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in the Methods section) found no association between patients experiencing pyrexia when 
defined as ≥38.0°C and outcomes, but did find that patients with “marked pyrexia” 
(>38.7°C) compared to those who experienced no/mild pyrexia (38.7°C)) had 
significantly worse neurologic outcomes at hospital discharge (Leary et al. 2013).  
 Two recent randomized trials, one in adults (“TTM trial”) (Nielsen et al. 2013) 
and one in children (Therapeutic Hypothermia After Pediatric Cardiac Arrest trial, or 
THAPCA) (Moler et al. 2015), randomized patients to receive active TTM at different 
goal temperatures, 33°C versus 36°C in the TTM trial and 33°C versus 36.8°C in the 
pediatric THAPCA trial. The null results from these studies raise questions regarding 
mechanisms by which TTM confers benefit: whether physiologic changes resulting from 
mild hypothermia or prophylaxis against pyrexia is the vital component (Rittenberger and 
Callaway 2013; Rittenberger and Callaway 2014). Although both studies failed to find a 
significant difference between the two temperature goals, the second study has been 
criticized as potentially underpowered – that the trend toward more positive outcomes in 
the group at goal temperature 33.0°C (p=0.14) is not statistically significant simply 
because there were not enough patients in the study (Geva, Tasker, Randolph 2015; 
Riess, Aufderheide, Yannopoulos 2015). One possible explanation for the statistical 
differences in the two studies is in the different temperatures for the “normothermia” arm 
(36.0°C compared to 36.8°C). In the TTM trial, a goal body temperature of 36°C resulted 
in an upper limit of the 95% confidence interval of recorded temperatures being between 
37.0-37.5°C; these patients were well protected from pyrexia (van der Jagt and Haitsma 
2015). The THAPCA trial, with its goal temperature 0.8°C higher than the 36°C arm in 
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the TTM trial may not provide the same protection against temperatures ≥38.0°C with 
similar confidence bounds, although this is not necessarily the case. If higher 
temperatures are indeed indicative of worsened outcomes, then permitting higher 
temperatures may be associated with worse outcomes, which may explain the trend 
toward better results in THAPCA patients treated at 33°C (Moler et al. 2015). 
This argument is supported by studies of the physiologic effects of elevated 
temperature on the brain. Laboratory investigations have suggested that a broad array of 
post-arrest pathophysiological processes is worsened by hyperthermia (Polderman 2008; 
Winters et al. 2013). Avoidance of pyrexia has been recommended in international 
resuscitation guidelines (Deakin et al. 2010; Peberdy et al. 2010), as pyrexia induces 
inflammatory cascades and increases neuronal excitotoxicity with neurotransmitter 
release, free radical production, increased intracellular glutamate concentration (Badjatia 
2009; Zhao et al. 1997), neuroinflammation, influx of excess calcium into injured brain 
cells leading to hyper-metabolism, trapping of heat in injured areas (Polderman 2009), 
and a generalized increase in metabolic rate (Lanier 1995; Polderman 2008; Polderman 
2009; Polderman 2015). As demonstrated in animal studies, high brain temperature, 
independent of initial severity of injury, can cause additional neurological damage 
(Polderman 2009; Wang et al. 2009). There is also a relationship between temperature 
changes and ischemia; post-ischemic injury is aggravated under hyperthermia (Busto et 
al. 1987; Dietrich et al. 1990; Kobayashi et al. 2008). This provides a scientific rationale 
for these findings on the deleterious effects of more markedly elevated temperatures.   
A number of limitations are inherent in this work. This study represented an 
analysis of a retrospective registry. As such, this study was limited to using predefined 
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data points and has the risk of data entry errors or inconsistencies.  Additionally, there 
may be information bias if the highest temperature was not recorded in the patient chart, 
which could result in misclassification. As a retrospective study, whether increased body 
temperature causes brain injury directly or merely acts as a surrogate marker for more 
severely damaged patients (Bro-Jeppesen et al. 2013; Winters et al. 2013) cannot be 
tested, although these findings are consistent with a large body of mechanistic work. 
Despite these limitations, use of a registry allows for a heterogeneous patient population, 
leading to greater external validity and generalizability.  
 
CONCLUSIONS 
In patients experiencing post-rewarming pyrexia, higher temperatures are 
associated with worse outcomes. Longer duration of time at pyrexic temperatures is only 
associated with worse outcomes at high temperatures (≥38.8°C), suggesting that 
avoidance of markedly elevated temperatures might improve outcomes.  
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CHAPTER 3 
Degree, duration, and timing of temperature elevation are associated with 
neurologic and survival outcomes in resuscitated cardiac arrest patients with post-
arrest pyrexia  
 
INTRODUCTION 
Approximately half of sudden cardiac arrest survivors suffer some degree of 
neurologic disability (Moulaert et al. 2009) from massive ischemic injury and subsequent 
reperfusion processes, known collectively as the post-cardiac arrest syndrome (PCAS) 
(Adrie et al. 2002; Neumar et al. 2008). Two randomized trials published in 2002 
demonstrated that post-arrest therapeutic hypothermia, also known as targeted 
temperature management (TTM), greatly improves neurologic outcomes and survival 
when applied early after successful resuscitation from out of hospital cardiac arrest 
(OHCA) associated with an initial shockable rhythm (VF/VT)) (Bernard et al. 2002; 
Hypothermia after Cardiac Arrest Study Group 2002). A large number of observational 
studies have confirmed and extended these findings, including evidence that TTM can be 
applied to arrests caused by other rhythms and to IHCA (Arrich and European 
Resuscitation Council Hypothermia After Cardiac Arrest Registry Study Group 2007; 
Busch et al. 2006; Lundbye et al. 2012; Oddo et al. 2006; Perman et al. 2015; Sagalyn et 
al. 2009; Schefold et al. 2009; Sunde et al. 2007). However, a recent study from Europe 
(Nielsen et al. 2013) has challenged the current paradigm of post-arrest TTM.  This 
investigation differed from the trials in 2002 in that both arms of the trial received active 
TTM, each with a different goal temperature: a “hypothermic” group with a goal of 33°C 
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and a “normothermic” group with an actively managed goal of 36°C.  The study found no 
significant difference in terms of neurologic outcome or mortality, which has raised the 
question of whether mild hypothermia is the important component of TTM treatment or if 
the avoidance of elevated temperatures is (Nielsen et al. 2013; Rittenberger and Callaway 
2013).  
 Because patients treated with TTM have their temperatures controlled, potentially 
masking variation and preventing extreme temperatures, we sought to explore the 
relationship between three different elements of post-arrest temperature and outcomes in 
patients not treated with TTM. Although studies examining the role of temperature in 
post-arrest patients prior to the widespread use of TTM exist, post-arrest care has 
changed dramatically since those works were conducted (Callaway et al. 2015; Hinchey 
et al. 2010; Kellum, Kennedy, Ewy 2006; Kellum et al. 2008; Lund-Kordahl et al. 2010; 
Neumar et al. 2008; Spaite et al. 2014). Additionally, the population of patients not 
treated with TTM has changed. The most recent studies evaluating post-arrest 
temperature include patients treated with TTM (Gebhardt et al. 2013; Suffoletto et al. 
2009), causing difficulty in effectively ascertaining the effects of temperature in patients 
not treated with TTM, a group that could serve to inform comparisons regarding the 
protective mechanisms of TTM (Rittenberger and Callaway 2013). Investigation of 
patients not treated with TTM provides an opportunity to expand the scientific 
understanding of neurologic mechanisms underlying PCAS and post-arrest temperature. 
 
METHODS 
To evaluate how body temperature during the 72 hours following successful 
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resuscitation from cardiac arrest is related to outcomes, the Penn Alliance for Therapeutic 
Hypothermia (PATH) registry was queried. PATH is an internet-based registry 
established by University of Pennsylvania investigators in 2010 that includes cardiac 
arrest data from pre-hospital, emergency department, and in-hospital settings with a focus 
on post-arrest care. With participation open to any US hospital, PATH supports the 
tracking of all patients who experience cardiac arrest and receive cardiopulmonary 
resuscitation, and currently includes cases from 34 hospitals.  Each patient record in 
PATH consists of 30 data elements required from all participating institutions. One 
hundred additional data elements are required for research participation and further 
optional data elements are also available to address specific research questions. Data are 
entered via a secure website, maintained on a password-protected encrypted server at the 
University of Pennsylvania, and collected retrospectively at each participating institution 
by trained PATH clinical data collection volunteers. Before entering data, data 
abstractors undergo structured training including mock case entry and case review. They 
are provided with a standardized data dictionary and subject to a formal auditing process 
(Leary et al. 2013). PATH currently supports 34 member hospitals and includes data 
from over 5000 cardiac arrests.  PATH includes the capability of collecting serial 
temperature measurements for successfully resuscitated patients.   
Serial temperatures in the 72 hours after successful resuscitation from cardiac 
arrest were evaluated in the current study. Only patients who did not receive TTM were 
included. Exclusion criteria were age <18 years; traumatic etiology of arrest; death in the 
first 24 hours post-arrest; and no recorded temperatures during the applicable time period.  
Both OHCA and IHCA were included. Pyrexia was defined as 38.0°C, consistent with 
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definitions used in other post-cardiac arrest studies on the effects of temperature (Benz-
Woerner et al. 2012; Bouwes et al. 2012; Bro-Jeppesen et al. 2013; Gebhardt et al. 2013; 
Leary et al. 2013; Suffoletto et al. 2009; Winters et al. 2013); additionally, this 
temperature is also used as part of systemic inflammatory response syndrome (SIRS) 
criteria in sepsis, a condition that has been found to have much in common with PCAS 
(Adrie et al. 2002; Neumar et al. 2008). Our primary outcome was neurologic status 
(measured by a Cerebral Performance Category (CPC) score dichotomized into 
“favorable” [CPC 1-2] and “unfavorable” [CPC 3-5]) and our secondary outcome was 
survival, both measured at hospital discharge. The CPC score measured at discharge has 
been found to be reliable in terms of predicting long-term prognosis, especially survival 
(Hsu et al. 2014; Pachys et al. 2014; Phelps et al. 2013). There were three predefined 
exposures: maximum temperature, duration of pyrexia, and timing of onset of first 
pyrexic temperature (described below); maximum temperature was the primary analysis 
for which the study was powered. 
Maximum temperature 
Maximum temperature was defined as the highest recorded temperature in the 72 
hours immediately post-arrest. Multiple classification approaches were used to account 
for different possibilities of how maximum temperature related to outcomes: as a 
continuous variable, as an ordinal variable (by one temperature degree), and as a 
dichotomous variable (≥38.0°C, yes/no) in separate models.  
Duration of pyrexia 
The duration of time a patient experienced a pyrexic temperature was calculated 
in three ways: a low estimate (included time between consecutive pyrexic temperatures 
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with an assumed 1 hour buffer for a pyrexic temperature followed by a non-pyrexic 
temperature (or vice versa)) (Gebhardt et al. 2013), a high estimate (included time 
between consecutive pyrexic temperatures with all time from the pyrexic temperature to 
the next non-pyrexic temperature recorded) (Gebhardt et al. 2013), and an estimate that 
assumed that the transition between a pyrexic to a non-pyrexic point indicated half of the 
time at a pyrexic temperature and half of the time at a non-pyrexic temperature. All 
estimates ended at 72 hours post-arrest. These calculations were repeated for every tenth 
of a degree, beginning with 38.0°C and ending with 42.6°C (the highest recorded 
temperature for any patients during the time period of interest), to measure the duration 
of time at or above each tenth of a degree and assess whether duration of time at 
increasing temperatures (e.g., 38.0°C, 38.1°C, 38.2°C, ….42.6°C) had different 
relationships to outcomes. Due to diversity in maximum temperature cut points across 
studies (Takino and Okada 1991; Zeiner et al. 2001), we analyzed each tenth of a degree 
to allow for a data-driven temperature threshold, as opposed to one predefined. Each 
measure of time then was treated first as a continuous variable (hours at temperature of 
interest), as an ordinal variable (divided by tertile), and as a dichotomous variable 
(above/below the median duration) for each temperature cut point.  
Timing of pyrexia onset 
Timing of onset of pyrexia was defined as the time between return of spontaneous 
circulation and the first recorded pyrexic temperature (≥38.0°C). Timing of onset of 
pyrexia was assessed in 5 ways: early (first 36 hours post-arrest) vs. late (second 36 hours 
post-arrest) onset, early (before the median) vs. late (after the median) onset, as a 
continuous variable (time from arrest to first temperature ≥38.0°C in hours), in deciles, 
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and in groups established using Jenks natural break optimization, a statistical technique 
that uses the distribution of data to determine naturally occurring groupings (Cox 2007; 
Jenks 1967).  
Patient types 
To combine all three elements of temperature examined in patients with a 
maximum temperature ≥38.0°C, 12 different patient types were created based on 
naturally occurring groupings, as determined by Jenks natural break optimization (Cox 
2007; Jenks 1967). There were two groups of maximum temperature (low versus high), 
two groups of duration of pyrexia (short versus long) and three groups of timing of onset 
of pyrexia (early versus middle versus late). These patient types then were analyzed with 
regard to neurologic and survival outcomes. Due to some patient types having a low 
number of patients, 16 additional patient types were created involving just two 
dimensions of temperature and the analyses were repeated. 
Other data analysis 
For maximum temperature, duration of pyrexia, and timing of onset of pyrexia, 
pre-, intra-, and post-arrest variables recorded in PATH were examined to explore 
potential confounders. Descriptive statistics used proportions, means and standard 
deviations, medians and interquartile ranges, and histograms to determine the proportion 
or prevalence and distribution of each variable. Each potential confounder was modeled 
separately with the outcome prior to use in a multivariate model. Any multivariate 
analyses used p<0.25 for covariate entry into the model (Maldonado and Greenland 1993; 
Mickey and Greenland 1989). Parsimonious models were created using backward 
stepwise procedures and likelihood ratio tests (Lemeshow and Hosmer 1982). Missing 
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data on covariates of more than 5% but no more than 15% were addressed using multiple 
imputation conducted using 20 iterations (StataCorp 2013) and combined using the “mi 
estimate” Stata command (Cañette and Marchenko 2013). Regression results were 
reported using odds ratios (ORs) and corresponding 95% confidence intervals (CIs). All 
data were analyzed using Stata v13.1 (Statacorp, College Station, TX). Additional 
analyses stratified patients by location of arrest (OHCA/IHCA) and by whether the 
patient regained arousal shortly post-arrest or remained comatose. Finally, each 
component, maximum temperature, duration of pyrexia, and timing of onset of pyrexic 
temperature, was tested to assess whether there was a univariate “threshold” value using 
receiver operating characteristic (ROC) curves and concordance statistics for 
discrimination. Post-estimation Hosmer-Lemeshow goodness of fit tables were used to 
assess the validity of each chosen cut-off. 
 
RESULTS 
Out of 578 patients from 8 hospitals in the PATH registry treated from 2001-2015 
who met inclusion criteria, 228 (39.5%) had at least one pyrexic temperature (≥38.0°C). 
Approximately 90% of patients with a pyrexic temperature had data regarding timing of 
pyrexia onset (206/228) and duration of pyrexia (205/228). Patients had a median age of 
65 (IQR: 55, 74) years, a median 7 (IQR: 3, 15) minute duration of arrest, 31.7% had an 
initial shockable rhythm, 30.8% were OHCA, and 57.3% regained arousal (defined as not 
eligible for TTM due to purposeful following of commands) shortly post-arrest.  With 
regard to outcomes, 62.3% of patients survived to hospital discharge; 84.7% had a CPC 
score of 1 or 2 at discharge.  Pyrexic patients only differed significantly from non-pyrexic 
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patients in terms of median age (pyrexic: 64 (IQR: 52, 72) versus non-pyrexic: 66 (IQR: 
56, 75); p=0.01), median duration of arrest (pyrexic: 8 (IQR: 4, 17) versus non-pyrexic: 6 
(IQR: 2, 14); p=0.01), and whether the patient regained arousal shortly post-arrest 
(pyrexic: 49% versus non-pyrexic: 63%, p=0.001; Table 4). 
Maximum temperature 
When examining the effects of maximum temperature on outcome in multivariate 
analysis, controlling for duration of arrest, whether the arrest was witnessed, location of 
arrest, initial rhythm, if intra-arrest epinephrine was given, etiology of arrest, whether the 
patient regained arousal shortly post-arrest, time between arrest and maximum 
temperature, year of arrest, and treating hospital, increased maximum temperature was 
significantly associated with worse outcomes in all pyrexic patients, in patients with an 
OHCA, and in patients who remained comatose after successful resuscitation (Table 5A).  
When analyzing the effect of a maximum temperature of <38.0°C versus 
≥38.0°C, there was a trend toward an opposite result; a temperature ≥38.0°C appeared to 
be protective with regard to neurologic outcome in all patients and in patients 
experiencing an IHCA and with regard to both neurologic outcome and survival in 
comatose patients (Table 5B), compared to a temperature <38.0°C. These results were the 
same when analyzed by ordinal temperature degree. There was no temperature threshold 
that was independently predictive of outcome. 
Duration of pyrexia 
There was no significant relationship between duration of pyrexia and outcomes 
in all patients unless duration was calculated as time ≥38.7°C, the first temperature that 
had a significant association with outcomes. When measuring duration of temperature 
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≥38.7°C, there was a significant association between longer duration and worse 
neurologic outcome and lower survival. When restricted to only OHCAs, longer duration 
was significantly associated with worse neurologic outcome and lower survival starting at 
a temperature of 38.3°C. Once duration of pyrexia was measured at 39.0°C, all patients, 
patients with an OHCA, patients with an IHCA, and patients who regained arousal 
shortly post-arrest had a significant association between longer duration and worse 
outcomes. Only patients who remained comatose did not have a significant association 
(Table 6). There was consistency between all three measures of duration of pyrexia; the 
reported results are from the estimate that assumed that the transition between a pyrexic 
to a non-pyrexic point indicated half of the time at a pyrexic temperature and half of the 
time at a non-pyrexic temperature, which represents the most moderate calculation. 
There were suitable pyrexia duration threshold values to serve as an independent 
predictor of outcome for all patients, patients with an OHCA, patients with an IHCA, and 
patients who regained consciousness shortly post-arrest. These thresholds ranged from 
2.5-6 hours at a certain pyrexic temperature, and varied due to strata of arrest and 
temperature measured (Table 7).  
Timing of pyrexia onset 
The relationship of the timing of onset of pyrexia to outcome varied by which 
subgroup of patients was analyzed: in comatose patients, both middle (10.2-24.5 hours 
post-arrest) and late (25.5-70.4 hours post-arrest) onset were associated with worse 
outcomes than early (0.2-10.0 hours post-arrest) onset. In all patients and those with 
OHCAs, the relationship was quadratic, with early and late onset being associated with 
better outcomes than middle onset in all patients and associated with better neurologic 
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outcome in OHCAs (Table 8; characteristics of patients based on their onset of pyrexia 
timing in Appendix Table 7). When limited to timing of onset of a temperature ≥38.8°C, 
there was some evidence that this pattern of timing held, but power constraints due to the 
reduced number of patients in each stratum precluded associative conclusions. There was 
no threshold value at which timing of pyrexia onset independently predicted outcomes. 
Patient types 
Combining these elements into “patient types” (Appendix Table 8), both timing of 
onset of pyrexia and maximum temperature were found to be associated with outcomes. 
Higher maximum temperature and timing of pyrexia onset between 10.2-24.5 hours post-
arrest were associated with worse outcomes. Patients with a low maximum temperature 
(38.0-39.0°C) and a timing of onset of pyrexia between 10.2-24.5 hours had significantly 
worse outcomes than a patient with a low maximum temperature and an early onset of 
pyrexia (0.0-10.5 h) (OR for CPC 1-2: 0.26 [95% CI: 0.10-0.67], p=0.01; OR for 
survival: 0.35 [95% CI: 0.13-0.93], p=0.04), as did a patient with a high maximum 
temperature (39.1°-42.6°C) and an early onset of pyrexia (OR for CPC 1-2: 0.26 [95% 
CI: 0.09-0.76], p=0.02; OR for survival: 0.17 [95% CI: 0.06-0.51], p<0.01; Figure 8).  
The importance of timing of pyrexia onset and maximum temperature was 
especially pronounced in patients who remained comatose, with worse neurologic 
outcomes in patients with a low maximum temperature (38.0-39.0°C)/short duration of 
pyrexia (0.0-10.5h)/middle timing of pyrexia onset (10.2-24.5h), patients with low 
temperature/short duration/late timing of pyrexia onset (25.5-70.4h), patients with high 
maximum temperature (39.1-42.6°C)/long duration of pyrexia (10.5-54.1h)/early timing 
of pyrexia onset (0.2-10.0h), patients with high temperature/long duration/middle timing, 
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and patients with high temperature/long duration/late timing compared to patients with 
low temperature/short duration/early timing. In terms of survival, patients with low 
temperature/short duration/middle timing, high temperature/long duration/early timing, 
and high temperature/long duration/late timing had worse survival compared to patients 
with low temperature/short duration/early pyrexia (Table 9). 
Other data analysis 
There was no univariate “threshold” value using receiver operating characteristic 
(ROC) curves that would allow for independent prediction of outcome for either 
maximum temperature or timing of onset of pyrexia.  
 
DISCUSSION 
 In this study of 578 post-arrest patients not treated with TTM, multiple aspects of 
post-arrest temperature were found to be important: maximum temperature, the 
combination of maximum temperature and duration of time at an elevated temperature, 
and timing of onset of pyrexia. We found a linear relationship between increasing 
maximum temperature and worsening neurologic and survival outcomes in pyrexic 
patients, although a seemingly protective effect of mild pyrexia when compared to 
37.0°C, which suggests that pyrexia is harmful at temperatures >38.0°C, the traditional 
definition of an elevated temperature (Benz-Woerner et al. 2012; Bouwes et al. 2012; 
Gebhardt et al. 2013; Leary et al. 2013; Neumar et al. 2008; Suffoletto et al. 2009; 
Winters et al. 2013). This was supported by the finding that there were discrete durations 
of time at or above certain pyrexic temperatures that were predictive of outcome, and that 
higher temperatures had lower duration thresholds (for example, in OHCAs, a cutoff of 
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≤5 hours at 38.8°C and a cutoff of ≤2.5 hours at 39.5°C both had excellent predictive 
value; in other words, patients could experience temperatures at 38.8°C for twice as long 
than they could at 39.5°C before the effects of pyrexia became detrimental). Finally, we 
found that timing of onset of pyrexia was associated with outcomes, in a manner than 
might partially mirror the phases of PCAS syndrome: early (0.2-10.0 hours), middle 
(10.2-24.5 hours), and late (25.5-70.4 hours). In the patients who remained comatose 
post-arrest (those most likely to have PCAS) (Neumar et al. 2008), both the patients with 
middle and late timing of pyrexia onset, which have similar timing to the “intermediate” 
PCAS phase (Neumar et al. 2008), are associated with worse outcomes. This could reflect 
the impact of the systemic ischemia/reperfusion response. 
 Similarly, relatively small clinical studies conducted prior to the widespread use 
of TTM support an association between pyrexia and poor outcomes in post-arrest patients 
(Bro-Jeppesen et al. 2013; Langhelle et al. 2003; Takasu et al. 2001; Takino and Okada 
1991; Zeiner et al. 2001). However, Takino et al found that hyperthermia (defined as 
>38.0°C) was associated with poor neurologic outcomes and temperatures above 39.0°C 
were associated with brain death (Takino and Okada 1991). In another clinical study, 
Zeiner et al found that for each degree over 37°C, the risk of an unfavorable neurologic 
recovery increased, with an odds ratio of 2.26 (Zeiner et al. 2001), which contradicts our 
finding that mild pyrexia is not harmful, but supports our assertion that temperature 
elevation beyond that is associated with worse outcomes. One explanation for our 
contradictory results is that mild pyrexia could be protecting against the infection 
commonly seen in post-arrest patients (Hypothermia after Cardiac Arrest Study Group 
2002; Sunde et al. 2007) by temporarily enhancing the immune system (Kluger et al. 
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1996; Mace et al. 2011; Repasky, Evans, Dewhirst 2013). Another possibility is that the 
patient populations studied are different. 
 Another study analyzed the effects of post-arrest duration of pyrexia, examining 
336 patients in the first 48 hours post-arrest, 65% of whom received TTM. We replicated 
their methodology in measuring duration of pyrexia for two of our three estimates of 
pyrexia duration, the low and high estimate. While both low and high duration estimates 
were associated with neurologic outcome in the patients treated with TTM in their study, 
there was no relationship between duration of pyrexia (defined as ≥38.0°C) and 
neurologic outcome in the patients not treated with TTM, which supports our finding 
when duration was analyzed at a temperature ≥38.0°C (Gebhardt et al. 2013). Another 
study of patients suffering from traumatic brain injury looked at the number of days a 
patient had a temperature ≥38.0°C and found that an increased number of days at a 
pyrexic temperature was associated with an increase in the likelihood of poor prognosis. 
The authors concluded that the amount of time at or above a pyrexic temperature may be 
an independent predictor for outcome (Bao et al. 2014). Although our study found similar 
results, that duration of time at an elevated temperature could be independently predictive 
of outcome, this only occurred when temperatures were at least 0.5°C above the 
commonly used threshold of 38.0°C. 
In a 2008 American Heart Association consensus statement, an approach to 
comparing mortality rates using physiologic markers of post-arrest injury commonly 
found in PCAS was suggested; this approach classifies the early post-arrest period as 20 
minutes post-ROSC to 6-12 hours post-ROSC, the intermediate period between 6-12 
hours and 72 hours post-ROSC, and the recovery phase as after 72 hours post-ROSC 
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(Neumar et al. 2008). When looking at the association between outcomes and timing of 
onset of pyrexia in comatose patients (arguably those with the most severe PCAS), 
patients had better outcomes in the “early phase”, 0-10 hours post-arrest, than in the 
“intermediate phase”, 10.2-72 hours post-arrest. In the other groups of patients, the 
worsening outcomes related to the “intermediate phase” was capped at 24.5 hours, with 
better outcomes between 25.5-72 hours, which could speak to a potentially different 
course of PCAS neurologic injury in comatose versus other patients. Additionally, 
laboratory investigations have suggested that many PCAS pathophysiological processes 
are worsened by pyrexia (Polderman 2008; Winters et al. 2013), which can intensify the 
neurologic injury caused by the ischemic insult of SCA and contributes to poor outcomes 
(Adrie et al. 2002; Badjatia 2009; Bernard et al. 2002; Deakin et al. 2010; Ginsberg et al. 
1992; Greer et al. 2008; Hickey et al. 2003; Hypothermia after Cardiac Arrest Study 
Group 2002; Langhelle et al. 2003; Neumar et al. 2015; Takasu et al. 2001; Takino and 
Okada 1991; Zeiner et al. 2001). This finding was contrary to that of Gebhardt et al, who 
found no association between timing of onset of pyrexia and outcomes, although their 
study only looked at the first 48 hours post-arrest and included both patients who had 
received TTM and those who did not (Gebhardt et al. 2013). 
 Clinically, if “lower” pyrexic temperatures (such as ≤38.5°C) are not particularly 
harmful and even possibly helpful, investigation into the ideal temperature threshold for 
treatment of pyrexia would be prudent. On the other hand, once a patient reaches an 
“elevated” pyrexic temperature, this study suggests that the length of time a patient 
experiences that temperature needs to be as short as possible; only a few hours at elevated 
temperatures are required before the duration of pyrexia becomes predictive of poor 
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outcomes. Moreover, the timing of temperature elevation may be a marker of continued 
PCAS injury.  
However, as this is a retrospective registry study, there is a need for further 
prospective studies in this area. This would reduce the limitations of using predefined 
data points and the potential risk of data entry errors or inconsistencies and information 
bias (such as if the highest temperature was not recorded in the patient medical record, 
which could result in misclassification). Additionally, there may be a relationship 
between the timing of onset of temperature ≥38.7°C that this study was underpowered to 
find. As a retrospective study, whether increased body temperature causes brain injury 
directly or merely acts as a surrogate marker for more severely damaged patients (Bro-
Jeppesen et al. 2013; Winters et al. 2013) cannot be tested, although our findings are 
consistent with a large body of mechanistic work. Use of only patients not treated with 
TTM may present a non-representative sample of all cardiac arrest patients, although this 
group was deliberately chosen to analyze temperature outside of TTM. Despite these 
limitations, use of a registry allows for a heterogeneous patient population, leading to 
greater external validity and generalizability.  
 
CONCLUSION 
In patients experiencing post-arrest pyrexia, higher pyrexic temperatures were 
associated with worse outcomes. Longer duration of pyrexia was associated with worse 
outcomes at higher temperatures and onset of pyrexia in the first 10 hours post-arrest was 
associated with better outcomes, suggesting that avoidance of high temperatures and 
pyrexia after 10 hours post-arrest might improve outcomes. 
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TABLES 
 
Table 1: Variables Explored for Registry Risk Standardization 
Age Sex Race 
Location of arrest Etiology of arrest Initial pulseless rhythm 
Whether patient went to the 
cardiac catheterization lab 
Whether patient went to the 
electrophysiology lab 
Whether patient regained 
consciousness shortly post-arrest 
Treatment with TTM Bystander CPR provided If arrest was witnessed 
If patient was transferred If intra-arrest epinephrine given Cumulative dose of intra-arrest 
epinephrine  Duration of arrest Year of arrest 
 
Table 2. Patient Demographics Stratified by Maximum Temperature in TTM-treated 
Patients 
 Maximum 
Temperature 
≥38.0°C (n=179) 
Maximum 
Temperature 
<38.0°C (n=286) 
p-value 
Age, years (mean±SD) 56.0±16.0 60.4±16.4 0.001 
Race 
   White 81 (45.8) 157 (56.5) 0.076 
   Black 84 (47.5) 108 (38.9)  
   Other 12 (6.8) 13 (4.7)  
Male 107 (59.8) 164 (57.3) ns 
Witnessed 118 (69.4) 195 (72.2) ns 
Cardiac Etiology of Arrest 116 (65.9) 184 (66.2) ns 
Out-of-Hospital Arrest 149 (83.2) 234 (81.8) ns 
Initial Rhythm 
   VF/VT 68 (39.5) 102 (38.5) ns 
   Asystole 35 (20.4) 61 (23.0)  
   PEA 69 (40.1) 102 (38.5)  
Duration of Arrest (median 
minutes) 
20 (IQR: 10, 29) 
18 (IQR: 10, 33) ns 
Survival to Discharge 93 (52.0) 118 (41.3) 0.024 
CPC 1-2 at Discharge 62 (34.8) 94 (33.0) ns 
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Table 3. Relationship of Temperature to Outcomes in TTM-treated Patients 
 Survival p-
value 
Neurologic 
Outcome 
p-value 
A: Relationship of Maximum Temperature to Outcomes 
All patients 0.25 (0.10-0.59) 0.002 0.30 (0.10-0.84) 0.022 
OHCA patients  0.43 (0.21-0.88) 0.022 0.10 (0.03-0.42) 0.002 
 
B: Relationship of Pyrexia (38.0oC) to Outcomes 
All patients 1.54 (1.00-2.35) 0.048 0.85 (0.52-1.40) 0.53 
   Patients with maximum     
   temperature ≥37oC 
1.46 (0.95-2.26) 0.088 0.85 (0.51-1.41) 0.519 
OHCA patients  1.36 (0.85-2.18) 0.205 1.07 (0.63-1.81) 0.799 
IHCA patients 5.58 (1.36-18.41) 0.005 1.23 (0.45-3.39) 0.689 
 
C: Relationship of Duration to Outcomes (in hours) 
Time 38.0oC 
All patients  1.03 (0.99-1.07) 0.205 1.02 (0.98-1.07) 0.366 
OHCA patients  1.03 (0.99-1.07) 0.207 1.04 (0.98-1.10) 0.163 
Time 38.8oC 
All patients  0.82 (0.72-0.93) 0.002 0.86 (0.75-1.00) 0.045 
OHCA patients  0.80 (0.69-0.93) 0.004 0.69 (0.54-0.89) 0.005 
 
Table 4. Patient Demographics Stratified by Maximum Temperature in Patients Not 
Treated with TTM 
 Maximum Temperature 
≥38°C (n=228) 
Maximum Temperature 
<38°C (n=350) 
p-value 
Age (median [IQR] years) 64 (52, 72) 66 (56, 75) 0.013 
Race 
   White 116 (53.5) 169 (51.5)  
   Black 92 (42.4) 142 (43.3) 0.814 
   Other 9 (4.2) 17 (5.2)  
Male 141 (61.8) 191 (54.6) 0.084 
Witnessed 185 (93.0) 257 (90.2) 0.283 
Cardiac Etiology of Arrest 118 (54.6) 205 (61.9) 0.089 
Out-of-Hospital Arrest 64 (28.1) 114 (32.6) 0.252 
Initial Rhythm 
   VF/VT 68 (31.3) 103 (32.0)  
   Asystole 32 (14.8) 45 (14.0) 0.965 
   PEA 117 (53.9) 174 (54.0)  
Duration of Arrest (median 
[IQR]  minutes) 
8 (4, 17) 
6 (2, 14) 0.012 
Regained Arousal Shortly 
Post-Arrest 
111 (48.7) 
220 (62.9) 0.001 
Survival to Discharge 141 (61.8) 219 (62.6) 0.860 
CPC 1-2 at Discharge 119 (52.2) 186 (53.1) 0.823 
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Table 5. Relationship of Temperature to Outcomes in Patients Not Treated with TTM 
 Survival p-
value 
Neurologic 
Outcome 
p-value 
A: Relationship of Maximum Temperature to Outcomes 
All patients 0.57 (0.39-0.83) 0.004 0.56 (0.37-0.85) 0.006 
OHCA patients  0.36 (0.14-0.88) 0.025 0.35 (0.12-1.01) 0.053 
Patients Remained Comatose 
Post-Arrest 
0.49 (0.27-0.90) 0.021 0.43 (0.22-0.85) 0.016 
 
B: Relationship of Pyrexia (38.0oC) to Outcomes 
All patients 1.43 (0.94-2.17) 0.093 1.51 (1.00-2.26) 0.048 
   Patients with maximum     
   temperature ≥37oC 
1.46 (0.95-2.26) 0.088 0.85 (0.51-1.41) 0.519 
IHCA patients  1.58 (0.99-2.53) 0.056 1.78 (1.11-2.83) 0.016 
Patients Remained Comatose 
Post-Arrest 
2.03 (1.16-3.57) 0.014 1.89 (1.05-3.41) 0.034 
 
 
Table 6. Association of Duration of Pyrexia and Outcome in Patients Not Treated with 
TTM 
 Survival p-value CPC 1-2 p-value 
Time at or above 38.3°C 
All Patients 0.99 (0.96-1.02) 0.458 0.98 (0.95-1.02) 0.313 
OHCA Patients 0.88 (0.79-0.98) 0.024 0.88 (0.79-0.98) 0.017 
IHCA Patients 0.99 (0.96-1.03) 0.594 0.99 (0.95-1.02) 0.427 
Patients Regained Arousal 
Shortly Post-Arrest 
0.93 (0.88-0.99) 0.019 0.94 (0.89-0.99) 0.021* 
Patients Remained Comatose 
Post-Arrest 
1.02 (0.97-1.07) 0.422 1.01 (0.97-1.05) 0.670 
Time at or above 38.7°C 
All Patients 0.95 (0.90-1.00) 0.034 0.94 (0.89-0.99) 0.030 
OHCA Patients 0.78 (0.66-0.92) 0.003 0.74 (0.60-0.92) 0.006 
IHCA Patients 0.97 (0.92-1.02) 0.211 0.95 (0.90-1.00) 0.071 
Patients Regained Arousal 
Shortly Post-Arrest 
0.88 (0.80-0.96) 0.006 0.89 (0.82-0.97) 0.007 
Patients Remained Comatose 
Post-Arrest 
0.99 (0.92-1.06) 0.744 0.97 (0.91-1.04) 0.392 
Time at or above 39.0°C 
All Patients 0.90 (0.84-0.97) 0.005 0.88 (0.81-0.97) 0.006 
OHCA Patients 0.74 (0.60-0.90) 0.003 0.68 (0.52-0.90) 0.006 
IHCA Patients 0.93 (0.86-1.00) 0.036 0.90 (0.83-0.98) 0.018 
Patients Regained Arousal 
Shortly Post-Arrest 
0.77 (0.65-0.91) 0.002 0.80 (0.69-0.93) 0.003 
Patients Remained Comatose 
Post-Arrest 
0.95 (0.88-1.04) 0.266 0.93 (0.85-1.02) 0.136 
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Table 7. Thresholds of Time at Pyrexic Temperatures Predictive of Outcome in Patients 
Not Treated with TTM 
 38.8°C 39.0°C 39.3°C 39.5°C 
All patients 
   Survival Time Threshold   5 hours  
   Survival AUC   0.70  
   CPC 1-2 Time Threshold     5 hours   
   CPC AUC  0.73   
OHCA patients 
   Survival Time Threshold 5 hours   2.5 hours 
   Survival AUC  0.78   0.93 
   CPC 1-2 Time Threshold    5 hours   2.5 hours 
   CPC AUC 0.78   0.88 
IHCA patients 
   Survival Time Threshold   5 hours  
   Survival AUC   0.73  
   CPC 1-2 Time Threshold      6 hours  
   CPC AUC   0.70  
Patients who gained arousal shortly post-arrest 
   Survival Time Threshold  5 hours   
   Survival AUC  0.82   
   CPC 1-2 Time Threshold     5 hours   
   CPC AUC  0.78   
 
Table 8. Association of Timing of Onset of Pyrexia to Outcomes in Patients Not Treated 
with TTM 
 Survival p-value CPC 1-2 p-value 
All Patients 
0.17-10.0 reference  Reference  
10.2-24.5 0.23 (0.10-0.54) 0.001 0.29 (0.12-0.70) 0.006 
25.5-70.4 1.11 (0.57-2.17) 0.758 1.47 (0.79-2.75) 0.225 
OHCA Patients 
0.17-10.0 reference  Reference  
10.2-24.5 0.07 (0.01-0.62) 0.017 0.29 (0.07-1.24) 0.094 
25.5-70.4 0.38 (0.04-3.87) 0.410 0.98 (0.21-4.58) 0.979 
IHCA Patients 
0.17-10.0 reference  Reference  
10.2-24.5 0.56 (0.24-1.32) 0.187 0.41 (0.18-0.95) 0.037 
25.5-70.4 0.64 (0.28-1.43) 0.276 0.78 (0.36-1.69) 0.524 
Patients Regained Arousal Shortly Post-Arrest 
0.17-10.0 reference  Reference  
10.2-24.5 0.60 (0.21-1.73) 0.342 0.59 (0.22-1.59) 0.298 
25.5-70.4 1.63 (0.54-4.97) 0.389 2.79 (0.96-8.08) 0.059 
Patients Remained Comatose Post-Arrest 
0.17-10.0 reference  Reference  
10.2-24.5 0.25 (0.09-0.71) 0.010 0.24 (0.09-0.66) 0.006 
25.5-70.4 0.28 (0.09-0.83) 0.022 0.24 (0.08-0.71) 0.009 
51 
 
 
 
Table 9. Association of Patient Types with Outcomes in Patients Not Treated with TTM 
 Survival p-
value 
CPC 1-2 p-
value 
All Patients 
High temperature–short duration–early 
onset 
0.75 (0.06-9.27) 0.823 0.33 (0.04-3.03) 0.329 
High temperature–short duration–middle 
onset 
0.25 (0.04-1.74) 0.161 0.33 (0.05-2.21) 0.255 
High temperature–short duration–late 
onset 
0.25 (0.01-4.92) 0.362 0.33 (0.02-6.37) 0.466 
High temperature–long duration–early 
onset 
0.43 (0.10-1.81) 0.248 0.24 (0.06-0.95) 0.041 
High temperature–long duration–middle 
onset 
0.15 (0.04-0.63) 0.009 0.10 (0.03-0.43) 0.002 
High temperature–long duration–late 
onset 
0.30 (0.06-1.51) 0.144 0.19 (0.04-0.94) 0.041 
Low temperature–short duration–early 
onset 
REFERENCE  REFERENCE  
Low temperature–short duration–middle 
onset 
0.40 (0.10-1.54) 0.184 0.24 (0.07-0.88) 0.031 
Low temperature–short duration–late 
onset 
0.55 (0.16-1.96) 0.359 0.55 (0.17-1.78) 0.318 
Low temperature–long duration–early 
onset 
1.00 (0.21-4.71) 0.99 1.00 (0.24-4.18) 0.999 
Low temperature–long duration–middle 
onset 
0.28 (0.07-1.20) 0.087 0.30 (0.07-1.19) 0.086 
Low temperature–long duration–late onset 0.50 (0.11-2.32) 0.376 0.67 (0.15-2.92) 0.590 
Patients Remained Comatose Post-Arrest 
High temperature–short duration–early 
onset 
n/a  n/a  
High temperature–short duration–middle 
onset 
0.06 (0.00-1.32) 0.074 0.06 (0.00-1.32) 0.074 
High temperature–short duration–late 
onset 
n/a  n/a  
High temperature–long duration–early 
onset 
0.22 (0.02-2.42) 0.217 0.08 (0.01-0.84) 0.036 
High temperature–long duration–middle 
onset 
0.07 (0.01-0.75) 0.027 0.03 (0.00-0.31) 0.004 
High temperature–long duration–late 
onset 
0.07 (0.01-0.82) 0.035 0.02 (0.00-0.30) 0.006 
Low temperature–short duration–early 
onset 
REFERENCE  REFERENCE  
Low temperature–short duration–middle 
onset 
0.10 (0.01-0.98) 0.049 0.05 (0.00-0.53) 0.013 
Low temperature–short duration–late 
onset 
0.11 (0.01-1.09) 0.060 0.05 (0.00-0.51) 0.012 
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Low temperature–long duration–early 
onset 
0.44 (0.02-9.03) 0.598 0.44 (0.02-9.03) 0.598 
Low temperature–long duration–middle 
onset 
0.09 (0.01-1.03) 0.053 0.09 (0.01-1.03) 0.053 
Low temperature–long duration–late onset 0.09 (0.01-1.03) 0.053 0.09 (0.01-1.03) 0.053 
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ILLUSTRATIONS 
 
Figure 1. Comparison of ROC Curves between Registry and Administrative Data in All 
Patients 
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Figure 2. Bland Altman Plot of Agreement between Registry and Administrative Risk 
Standardization Models in All Patients 
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Figure 3. Calibration Plot for Registry Data in All Patients 
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Figure 4. Calibration Plot for Administrative Data in All Patients 
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Figure 5. Comparison of ROC Curves between Registry and Administrative Data in Out-
of-Hospital Cardiac Arrest 
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Figure 6. Comparison of ROC Curves between Registry and Administrative Data in In-
Hospital Cardiac Arrest 
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Figure 7. Association between Maximum Temperature and Neurologic Outcome in 
TTM-treated Patients. The data are presented as the marginal probability (with 95% 
confidence interval) of a favorable outcome (defined as a Cerebral Performance Category 
[CPC] score of 1-2 at hospital discharge) given maximum temperature, controlling for 
initial rhythm, whether the arrest was witnessed, duration of arrest, age, duration of TTM 
maintenance, and year of arrest.  
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Figure 8. Association between Maximum Temperature, Timing of Pyrexia Onset, and 
Neurologic Outcome in Patients Not Treated with TTM. The data are presented as the 
marginal probability (with 95% confidence interval) of a favorable outcome (defined as a 
Cerebral Performance Category [CPC] score of 1-2 at hospital discharge) given 
maximum temperature and timing of pyrexia onset. Low temp = 38.0°C -39.0°C; high 
temp=39.1°C-42.6°C; early onset=0.2-10.0 hours post-arrest; middle onset=10.2-24.5 
hours post-arrest; late onset=24.5-70.4 hours post-arrest 
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APPENDIX 
Appendix Table 1: Patient Demographics in Registry Data 
 Matched 
N=2453 
Not Matched 
N=169 
p-value 
Age (median) 63 (51, 74) 63 (51, 74) 0.668 
Male 1409 (57.8) 97 (57.4) 0.915 
Race    
   White 967 (44.1) 52 (31.1)  
   Black  1088 (49.6) 99 (59.3) 0.003 
   Other 140 (6.4) 16 (9.6)  
Initial Rhythm    
   Asystole 604 (26.2) 40 (26.5)  
   PEA 1129 (49.0) 59 (39.1) 0.017 
   VF/VT 571 (24.8) 52 (34.4)  
Cardiac Etiology of Arrest 899 (60.6) 124 (75.6) <0.001 
OHCA 1305 (53.7) 125 (74.4) <0.001 
Witnessed Arrest 1066 (74.8) 136 (82.9) 0.022 
Bystander CPR (OHCA only) 144 (26.3) 28 (26.9) 0.899 
Epinephrine Given 1031 (83.5) 118 (73.3) 0.001 
Epinephrine Dose (median) 2 (0, 3) 1 (0, 3) 0.049 
Duration of Arrest (median)* 11 (5, 26) 21 (10, 34) <0.001 
ROSC achieved 1532 (62.5) 169 (100.0) <0.001 
TTM Performed* 473 (19.8) 133 (11.5) <0.001 
Patient Regained Consciousness after ROSC* 356 (17.4) 35 (31.3) <0.001 
Survival to Hospital Discharge 633 (25.8) 73 (43.2) <0.001 
CPC at Hospital Discharge 486 (20.0) 65 (38.5) <0.001 
*only calculated on patients with ROSC 
 
Appendix Table 2: Administrative Data Elements Used in Risk Standardization Model 
for All Patients 
Atrial Fibrillation (427.31) Age Opioid dependence (304) 
Anoxic Brain Damage (348.1) Any use of atropine (order) Blood culture (order) 
Cardiac Panel (order) Annuloplasty (35.33) CK (order) 
Blood alcohol level taken 
(order) 
Pure hypercholesterolemia 
(272) 
150 mg of Amiodarone 
(order) 
Emergency endotracheal 
intubation (31500) 
Human immunodeficiency 
virus [HIV] disease (42) 
Dissection of thoracic aorta 
(441.01) 
Right heart angiocardiogram 
(88.52) 
Malignant neoplasm of ovary 
and other uterine adnexa (183) 
Respiratory failure (518.81, 
518.83, 518.84, 799.1) 
Any use of cistatracurium 
(order) 
Fiber-optic bronchoscopy 
(33.22) 
Toxic encephalopathy 
(349.82) 
Rheumatic heart failure 
(398.91) 
Obstructive sleep apnea 
(327.23) 
Pneumococcal pneumonia 
(481) 
Compression of brain (348.4) Cerebral edema (348.5) Urinary tract infection (599) 
Secondary malignant neoplasm 
of respiratory and digestive 
systems (197) 
Methicillin-resistant 
Staphylococus aureus 
septicemia (38.11) 
Acute venous embolism and 
thrombosis of other specified 
veins (453.8) 
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Right heart cardiac 
catheterization (37.21) 
Left heart cardiac 
catheterization (37.22) 
Right/left heart cardiac 
catheterization (37.23) 
Tricuspid valve disease (397) Food/vomit pneumonitis (507) Bone marrow biopsy (41.31) 
Cardiogenic shock (785.51) Hemopericardium (423) Long QT syndrome (426.82) 
Takotsubo syndrome (429.83) Aortic atherosclerosis (440) Pulmonary collapse (518) 
Perforation of intestine (569.83) History of tobacco use 
(V15.82) 
Any use of nitroglycerin 
(order) 
Venous blood gas (order) Acute necrosis of liver (570) Acute kidney failure (584.9) 
Chronic kidney disease stage V 
(585.5) 
Other intubation of respiratory 
tract (96.05) 
Malfunctioning cardiac 
pacemaker (996.01) 
Cellulitis of neck (682.1) Drug dermatitis (693) Coma (780.01) 
Persistent vegetative state 
(780.03) 
Measure blood oxygen level 
(94760) 
Injection or infusion of 
immunoglobulin (99.14) 
Bacteremia (790.7) AICD check (89.49) Anaphylactic shock (995) 
Insert endotracheal tube (96.04) Sepsis (995.91) Atrial cardioversion (99.61) 
Insertion of drug-eluting 
coronary artery stent(s) (36.07) 
Packed red blood cell use 
(order) 
Chronic kidney disease 
(585.9) 
Malfunctioning prosthetic heart 
valve (996.02) 
Ventilator associated 
pneumonia (997.31) 
Accidental poisoning –
psychstimulant (E85.42) 
Cardiology/Cardiovascular 
Consultation (order) 
Cardiopulmonary resuscitation 
(92950, 93.93, 99.60) 
Do not resuscitate order 
(V49.86, order) 
1 mg of Epinephrine (order) E. coli infection (41.4) Fresh frozen plasma (order) 
Hypoxemia (799.02) Race Year of arrest 
Morbid obesity (278.01) Chest X-ray (order) Arterial blood gas (order) 
Urine culture (order) Chest X-ray (order) 500 mg of Flagyl (order) 
Lymphoid leukemia (204) CK-MB & Troponin (order) CK-MB Isoenzyme (order) 
Intestinal infection due to 
clostridium difficile (8.45) 
Insertion Of Intercostal 
Catheter For Drainage (34.04) 
Dopamine 800 mg infusion 
(order) 
Hemiplegia (342.9) Atrioventricular block (426.1) Liver transplant (50.59) 
Angioplasty or atherectomy of 
other non-coronary vessel(s) 
(39.5) 
Acute or chronic combined 
systolic and diastolic heart 
failure (428.41, 428.43) 
Open and other replacement 
of aortic valve with tissue 
graft (35.21) 
Open and other replacement of 
aortic valve (35.22) 
Critical illness myopathy 
(359.81) 
Insertion of other 
(naso)gastric tube (96.07) 
(Aorto)coronary bypass of two 
coronary arteries (36.12) 
(Aorto)coronary bypass of 
three coronary arteries (36.13) 
Other gram negative bacteria 
(41.85) 
Systemic inflammatory 
response syndrome due to 
noninfectious process without 
acute organ dysfunction 
(995.93) 
Emergency department visit 
for the evaluation and 
management of a patient, high 
complexity medical decision 
making (99285) 
Initial insertion of 
transvenous leads 
[electrodes] into ventricle or 
atrium and ventricle (37.71, 
37.72) 
Removal of lead(s) [electrode] 
without replacement (37.77) 
Respiratory system disease 
(519.8) 
Implantable heart assist 
system (37.66) 
Extracorporeal circulation 
auxiliary to open heart surgery 
(39.61) 
Acute myocardial infarction of 
inferoposterior wall, initial 
episode of care (410.31) 
Mobitz (type) II 
atrioventricular block 
(426.12) 
Coronary atherosclerosis of 
native coronary artery (414.01) 
Chronic ischemic heart disease 
(414.8) 
Intermediate coronary 
syndrome (411.1) 
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Other diagnostic procedures on 
heart and pericardium (37.29) 
Enteral infusion of 
concentrated nutritional 
substances (96.6) 
Complications of 
transplanted bone marrow 
(996.85) 
Percutaneous [endoscopic] 
gastrostomy [PEG] (43.11) 
Occlusion and stenosis of 
carotid artery (433.1) 
Cerebral embolism with 
cerebral infarction (434.11) 
Acute venous embolism and 
thrombosis of other specified 
veins (453.84) 
Chronic venous embolism and 
thrombosis of internal jugular 
veins (453.76) 
Chronic venous embolism 
and thrombosis of other 
thoracic veins (453.77) 
Local infection due to central 
venous catheter (999.33) 
Other specified disorders of 
circulatory system (459.89) 
Pulmonary artery wedge 
monitoring (89.64) 
Personal history of transient 
ischemic attack (TIA), and 
cerebral infarction without 
residual deficits (V12.54) 
Personal history of (corrected) 
congenital malformations of 
heart and circulatory system 
(V13.65) 
Continuous invasive 
mechanical ventilation for 96 
consecutive hours or more 
(96.72) 
Pacemaker (414.06) Sepsis (order)  
Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, 
documentation of selected vessel patency, concurrent real-time ultrasound visualization of 
vascular needle entry, with permanent recording and reporting (76937) 
Any poisoning (963.0, 963.1, 964.2, 965.00, 965.02, 965.09, 965.8, 967.0, 967.8, 969.03, 969.3, 
969.7, 969.72, 970.81, 971.2, 971.3, 972.6, E85.04, E85.1, E85.29, E85.42, E85.55, E85.56, 
E85.82, E85.89, E868.9, E95.00, E95.01, E95.04, E980.2) 
Implantation of cardiac resynchronization defibrillator or automatic cardioverter/ defibrillator, 
total system (0.51, 37.94) 
 
Appendix Table 3: Administrative Data Elements Used in Risk Standardization Model 
for Out-of-Hospital Cardiac Arrest Patients 
Atrial Fibrillation (427.31) Age 150 mg of Amiodarone (order) 
Spinal tap (3.31) Any use of aspirin (order) Hyperpotassemia (276.7) 
Delirium due to conditions 
classified elsewhere (293) 
Ventilator associated 
pneumonia (997.31) 
Cardiopulmonary resuscitation 
(92950) 
Anoxic Brain Damage 
(348.1) 
Pure hypercholesterolemia 
(272) 
Insert endotracheal tube 
(96.04) 
Cardiogenic shock (785.51) Cerebral edema (348.5) Food/vomit pneumonitis (507) 
Bacteremia (790.7) Acidosis (276.2) Anaphylactic shock (995) 
Fluid overload (276.69) Sepsis (995.91) Fresh frozen plasma (order) 
Intestinal infection due to 
clostridium difficile (8.45) 
Insertion of drug-eluting 
coronary artery stent(s) (36.07) 
Do not resuscitate order 
(V49.86, order) 
Obesity (278) Race Year of arrest 
Hemiplegia (342.9) Any use of epinephrine (order) Hemodialysis (39.95) 
Other pulmonary embolism 
and infarction (415.19) 
Chronic ischemic heart disease 
(414.8) 
Other gram negative bacteria 
(41.85) 
Percutaneous [endoscopic] 
gastrostomy [PEG] (43.11) 
Insertion of non-drug-eluting 
coronary artery stent(s) (36.06) 
Implant of pulsation balloon 
(37.61) 
Acute myocardial infarction 
of other inferior wall, initial 
episode of care (410.41) 
Insertion of temporary 
transvenous pacemaker system 
(37.78) 
Video and radio-telemetered 
electroencephalographic 
monitoring (89.19) 
Coronary atherosclerosis of Acute myocardial infarction of Injection or infusion of other 
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native coronary artery 
(414.01) 
other anterior wall, initial 
episode of care (410.11) 
therapeutic or prophylactic 
substance (99.2) 
Venous catheterization, not 
elsewhere classified (38.93) 
Interruption of the vena cava 
(38.7) 
Insertion of two vascular stents 
(0.46) 
Other dependence on 
machines, Appendix oxygen 
(V46.2) 
Other complications due to 
renal dialysis device, implant, 
and graph (996.73) 
Other and unspecified 
Escherichia coli [E. coli] 
(41.49) 
Septicemia (38.9) Mitral valve disorder (424) Ventricular fibrillation (427.41) 
Sinoatrial node dysfunction 
(427.81) 
Chronic systolic heart failure 
(428.22) 
Acute on chronic systolic heart 
failure (428.23) 
Unspecified acute edema of 
lung (518.4) 
Angiocardiography of left 
heart structures (88.53) 
Combined right and left heart 
angiocardiography (88.54) 
Old myocardial infarct (412) Packed cell transfusion (99.04) Foreign body in trachea (934) 
Insertion of temporary 
indwelling catheter, simple 
(51702) 
Continuous invasive 
mechanical ventilation for less 
than 96 consecutive hours 
(96.71) 
Continuous invasive 
mechanical ventilation for 96 
consecutive hours or more 
(96.72) 
Poisoning by cocaine 
(970.81) 
Arterial pressure monitor 
(89.61) 
Any use of nitroglycerin 
(order) 
Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, 
documentation of selected vessel patency, concurrent real-time ultrasound visualization of 
vascular needle entry, with permanent recording and reporting (76937) 
Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode 
recording, when performed, follow-up or limited study (93308) 
Emergency department visit for the evaluation and management of a patient, high complexity 
medical decision making (99285) 
 
Appendix Table 4: Administrative Data Elements Used in Risk Standardization Model 
for In-Hospital Cardiac Arrest Patients 
Age Acidosis (276.2) Opioid dependence (304) 
Right heart angiocardiogram 
(88.52) 
Human immunodeficiency 
virus [HIV] disease (42) 
Acute and chronic respiratory 
failure (518.84) 
Takotsubo syndrome (429.83) Annuloplasty (35.33) Urinary tract infection (599) 
Compression of brain (348.4) Shock (785.5) Long QT syndrome (426.82) 
Secondary malignant 
neoplasm of respiratory and 
digestive systems (197) 
Angioplasty or atherectomy of 
other non-coronary vessel(s) 
(39.5) 
Initial insertion of transvenous 
leads [electrodes] into ventricle 
(37.71) 
Right heart cardiac 
catheterization (37.21) 
Left heart cardiac 
catheterization (37.22) 
Chronic kidney disease stage V 
(585.5) 
Fiber-optic bronchoscopy 
(33.22) 
Food/vomit pneumonitis 
(507) 
Obstructive sleep apnea 
(327.23) 
Spinal tap (3.31) Acute necrosis of liver (570) Sepsis (995.91) 
Persistent vegetative state 
(780.03) 
CK-MB and troponin order in 
the ER (order) 
Do not resuscitate status 
(V49.86) 
AICD check (89.49) Drug dermatitis (693) Coma (780.01) 
Malfunctioning prosthetic 
heart valve (996.02) 
Ventilator associated 
pneumonia (997.31) 
Subarachnoid hemorrhage 
(852.05, 430) 
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Perforation of intestine 
(569.83) 
Percutaneous [endoscopic] 
gastrostomy [PEG] (43.11) 
Septicemia due to escherichia 
coli [E. coli] (038.42) 
Friedländer's bacillus 
infection in conditions 
classified elsewhere and of 
unspecified site (041.3) 
Implantation or replacement 
of automatic cardioverter/ 
defibrillator, total system 
(37.94) 
Other pulmonary insufficiency, 
not elsewhere classified 
(518.82) 
Hypoxemia (799.02) Arterial blood gas (order) Year of arrest 
Critical illness myopathy 
(359.81) 
Dependence on respirator, 
status (V46.11) 
Other respiratory complications 
(997.39) 
Intestinal infection due to 
clostridium difficile (8.45) 
Intermediate coronary 
syndrome (411.1) 
History of sudden cardiac 
arrest (V12.53) 
Hemiplegia (342.9) Severe sepsis (995.92) Liver transplant (50.59) 
(Aorto)coronary bypass of 
two coronary arteries (36.12) 
(Aorto)coronary bypass of 
three coronary arteries (36.13) 
Other diagnostic procedures on 
heart and pericardium (37.29)  
Extracorporeal circulation 
auxiliary to open heart surgery 
(39.61) 
Chronic venous embolism and 
thrombosis of internal jugular 
veins (453.76) 
Chronic venous embolism and 
thrombosis of other thoracic 
veins (453.77) 
Acute venous embolism and 
thrombosis of other specified 
veins (453.84) 
Enteral infusion of 
concentrated nutritional 
substances (96.6) 
Pseudomonas infection in 
conditions classified elsewhere 
and of unspecified site (041.7) 
Chronic hepatitis C with 
hepatic coma (070.44) 
Local infection due to central 
venous catheter (999.33) 
Critical illness polyneuropathy 
(357.82) 
Infusion of a vasopressor 
(0.17) 
Open aortic valvuloplasty 
(35.11) 
Hemiplegia/hemiparesis 
(438.2) 
Noninvasive programmed 
electrical stimulation [NIPS] 
(37.20) 
Initial insertion of transvenous 
leads [electrodes] into atrium 
and ventricle (37.72) 
Percutaneous transluminal 
coronary angioplasty [PTCA] 
(00.66) 
Candidiasis of lung (112.4) Obesity (278) Diagnostic ultrasound of heart 
(88.72) 
Implant of pulsation balloon 
(37.61) 
Initial insertion of dual-
chamber device (37.83) 
Interruption of the vena cava 
(38.7) 
Occlusion and stenosis of 
carotid artery with cerebral 
infarction (433.11) 
Central venous catheter 
placement with guidance 
(38.97) 
Other specified alveolar and 
parietoalveolar 
pneumonopathies (516.8) 
Angiocardiography of venae 
cavae (88.51) 
Other pulmonary embolism 
and infarction (415.19) 
Other primary 
cardiomyopathies (425.4) 
Respiratory arrest (799.1) Systolic heart failure (428.2) Intracerebral hemorrhage (431) 
Other second degree 
atrioventricular block (426.13) 
Pneumonia due to 
Pseudomonas (482.1) 
Influenza with pneumonia 
(487) 
Osteoporosis (733) Syncope and collapse (780.2) Retention of urine (788.2) 
Continuous invasive 
mechanical ventilation for less 
than 96 consecutive hours 
(96.71) 
Continuous invasive 
mechanical ventilation for 96 
consecutive hours or more 
(96.72) 
Chronic stomach ulcer with 
hemorrhage (531.4) 
Complete kidney transplant 
(996.81) 
Complete liver transplant 
(996.82) 
Complete lung transplant 
(996.84) 
Insertion of temporary non-implantable extracorporeal circulatory assist device (37.62) 
Suicide and self-inflicted poisoning by other specified drugs and medicinal substances (E95.04) 
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Appendix Table 5. Patient Types for Patients Treated with TTM 
 n Maximum 
temperature 
(
o
C) 
Duration 
of Pyrexia 
(hours) 
Timing 
(hours) 
Low temperature – short duration – early timing 37 38.00-38.72  0.40-9.15  0.0-16.5  
Low temperature – short duration – middle timing 13 38.00-38.72  0.40-9.15  18.0-40.2  
Low temperature – short duration – late timing 14 38.00-38.72  0.40-9.15  43.4-70.9  
Low temperature – long duration – early timing 25 38.00-38.72  9.75-60.75  0.0-16.5  
Low temperature – long duration – middle timing 21 38.00-38.72  9.75-60.75  18.0-40.2  
Low temperature – long duration – late timing 5 38.00-38.72  9.75-60.75  43.4-70.9  
High temperature – short duration – early timing 10 38.78-42.20  0.40-9.15  0.0-16.5  
High temperature – short duration – middle timing 2 38.78-42.20  0.40-9.15  18.0-40.2  
High temperature – short duration – late timing 1 38.78-42.20  0.40-9.15  43.4-70.9  
High temperature – long duration – early timing 38 38.78-42.20  9.75-60.75  0.0-16.5  
High temperature – long duration – middle timing 10 38.78-42.20  9.75-60.75  18.0-40.2  
High temperature – long duration – late timing 3 38.78-42.20  9.75-60.75  43.4-70.9  
 
Appendix Table 6. Potential Covariates for Patients Treated with TTM 
Sex Age Year of arrest Race 
Intra-arrest 
epinephrine given 
Cumulative dose of 
intra-arrest epinephrine 
Duration of TTM 
maintenance 
Duration of TTM 
rewarming 
Treating hospital Witnessed arrest Bystander CPR Duration of arrest 
Location of arrest Initial pulseless rhythm Length of hospital 
stay 
Time to TTM target 
temperature 
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Appendix Table 7. Characteristics of Patients by Timing of Onset of Pyrexia in Patients 
Not Treated with TTM 
 “Early Onset” 
(0.2-10.0 hours 
post-arrest; 
n=63) 
“Middle Onset” 
(10.2-24.5 
hours post-
arrest; n=70) 
“Late Onset” 
(25.5-70.4 
hours post-
arrest; n=73) 
p-
value 
Age (median [IQR] years) 61 [48, 71] 65 [56, 74] 66 [55, 75] 0.127 
Race     
   White 34 (56.7) 32 (47.1) 40 (57.1)  
   Black 22 (36.7) 32 (47.1) 30 (42.9) 0.140 
   Other 4 (6.7) 4 (5.9) 0 (0.0)  
Male 40 (63.5) 42 (60.0) 48 (65.8) 0.773 
Witnessed 47 (94.0) 59 (95.2) 62 (92.5) 0.924 
Cardiac Etiology of Arrest 32 (52.5) 37 (56.9) 35 (50.7) 0.762 
Out-of-Hospital Arrest 11 (17.5) 27 (38.6) 19 (26.0) 0.023 
Initial Rhythm     
   VF/VT 22 (35.5) 15 (22.7) 25 (36.2)  
   Asystole 10 (16.1) 7 (10.6) 11 (15.9) 0.187 
   PEA 30 (48.4) 44 (66.7) 33 (47.8)  
Duration of Arrest (median 
[IQR]  mins) 
7 [4, 16] 10 [4, 20] 8.5 [4, 16] 0.387 
Regained Arousal Shortly 
Post-Arrest 
35 (55.6) 30 (42.9) 40 (54.8) 0.246 
Survival to Discharge 47 (74.6) 36 (51.4) 48 (65.8) 0.019 
CPC 1-2 at Discharge 40 (63.5) 27 (38.6) 43 (58.9) 0.008 
 
 
Appendix Table 8. Patient Types for Patients Not Treated with TTM 
 n Maximum 
temperature 
(°C) 
Duration 
of 
Pyrexia 
(h) 
Timing 
of Onset 
(h) 
Low temperature – short duration – early onset 20 38.0-39.0  0.0-10.5 0.17-10.0 
Low temperature – short duration – middle onset 26 38.0-39.0 0.0-10.5 10.2-24.5 
Low temperature – short duration – late onset 45 38.0-39.0 0.0-10.5 25.5-70.4 
Low temperature – long duration – early onset 20 38.0-39.0 10.5-54.1 0.17-10.0 
Low temperature – long duration – middle onset 17 38.0-39.0 10.5-54.1 10.2-24.5 
Low temperature – long duration – late onset 15 38.0-39.0 10.5-54.1 25.5-70.4 
High temperature – short duration – early onset 4 39.1-42.6 0.0-10.5 0.17-10.0 
High temperature – short duration – middle onset 6 39.1-42.6 0.0-10.5 10.2-24.5 
High temperature – short duration – late onset 2 39.1-42.6 0.0-10.5 25.5-70.4 
High temperature – long duration – early onset 19 39.1-42.6 10.5-54.1 0.17-10.0 
High temperature – long duration – middle onset 21 39.1-42.6 10.5-54.1 10.2-24.5 
High temperature – long duration – late onset 11 39.1-42.6 10.5-54.1 25.5-70.4 
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Appendix Figure 1. Bland Altman Plot of Agreement between Registry and 
Administrative Risk Standardization Models in Out-of-Hospital Cardiac Arrest 
 
 
Appendix Figure 2. Bland Altman Plot of Agreement between Registry and 
Administrative Risk Standardization Models in In-Hospital Cardiac Arrest 
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